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Roles of RNF20, an E3 Ubiquitin Ligase,  
in Hepatic Lipid Metabolism and Kidney Cancer 
 
Jae Ho Lee 
 
Lipid metabolism is crucial for cell growth and survival by regulating 
energy homeostasis, signaling cascade, and membrane integrity. Accordingly, 
abnormal regulation of lipid metabolism is closely associated with metabolic 
disorders and tumorigenesis. In liver, de novo lipogenesis is hormonally and 
nutritionally controlled by sterol regulatory element-binding protein 1c (SREBP1c). 
SREBP1c is a key transcription factor for fatty acid synthesis during the 
postprandial state. Hepatic SREBP1c is rapidly suppressed by fasting signals to 
prevent futile lipogenic pathways. However, the molecular mechanisms that control 
SREBP1c turnover in response to fasting status are not thoroughly understood. 
Moreover, accumulating evidences have demonstrated that activated SREBP1c is 
involved in lipid storage in cancer cells. Although SREBP1c is associated with 
tumor development, progression and migration, eventually leading to poor 
prognosis, it remains unclear how SREBP1c would contribute to ectopic lipid 
storage and tumorigenesis in cancer cells. 
In the chapter one, I demonstrated that SREBP1c is ubiquitinated by ring 
finger protein 20 (RNF20), an E3 ubiquitin ligase. The RNF20-induced SREBP1c 
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ubiquitination suppresses hepatic lipid metabolism upon protein kinase A (PKA),  
a major signaling molecule for nutritional deprivation. In hepatocytes, glucagon 
and activated PKA stimulate RNF20 expression and subsequently downregulate 
lipogenic activity. In obese db/db mice, hepatic RNF20 overexpression alleviates 
fatty liver by reducing lipogenic activity via SREBP1c suppression. This study 
suggests that RNF20 would act as a negative regulator of hepatic lipid metabolism 
through SREBP1c degradation upon PKA activation. Thus, these findings enhance 
our understandings of how SREBP1c is able to turn off hepatic lipid metabolism 
during fasting. 
In the chapter two, I revealed that downregulation of RNF20 promotes 
tumorigenesis in clear cell renal cell carcinoma (ccRCC), which is characterized by 
ectopic lipid accumulation, following consequent activation of SREBP1c.       
In ccRCC tumor tissues, RNF20 is downregulated, accompanied with lipogenic 
activation and poor prognosis. In cultured ccRCC cells and xenograft studies, 
RNF20 overexpression represses lipogenesis and cell proliferation by inhibiting 
SREBP1c. In this study, pituitary tumor-transforming gene 1 (PTTG1) has been 
identified as a novel target gene of SREBP1c, and PTTG1 plays a crucial role in 
cell cycle progression in ccRCC through SREBP1c. In ccRCC cells, suppression of 
SREBP1 by either genetic knockdown or pharmacological inhibitor betulin 
attenuates cell proliferation, accompanied with decreased expression of PTTG1 and 
cell cycle genes. 
Taken together, this study provides a clue to understand how SREBP1c is 
regulated by RNF20 to modulate lipid homeostasis and underscores the close 
relationship between lipid metabolism and tumorigenesis in ccRCC, where the 
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RNF20-SREBP1c axis would be important for lipogenesis and cell cycle 
progression. Therefore, these data suggest that RNF20 might be a useful target for 
ameliorating metabolic disorders and certain cancers associated with increased 
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I. Lipid metabolism in liver 
 About 40% of the body‟s caloric intake is derived from lipids. Lipids 
consist of diverse water-insoluble molecules including triacylglycerides, 
phosphoglycerides, sterols, and sphingolipids. Various lipid metabolites act as 
energy sources, signaling molecules, and structural components of cellular 
membranes. For example, fatty acids are one of key components of 
triacylglycerides, which are primarily used for energy storage. Phosphoglycerides, 
together with sterols and sphingolipids, represent the major structural components 
of cellular membranes. Furthermore, lipids contribute to act as insulating material 
in the subcutaneous tissues. Lipid metabolites are also involved in signaling 
pathways by acting as second messengers. Thus, it is likely that alteration in lipid 
metabolism would influence various cellular processes including cell growth, 
proliferation, differentiation, and survival (Bretscher and Raff, 1975; Divecha and 
Irvine, 1995; Liscovitch and Cantley, 1994). 
Liver is one of the key organs in the regulation of lipid metabolism. In 
liver, fatty acids are originated from three major sources; (i) absorption from 
dietary lipid (chylomicrons), (ii) hydrolysis of triglycerides from adipose tissues 
(lipolysis), and (iii) liver-specific lipases de-esterify triglycerides to release free 
fatty acids (Lands, 1965; Nguyen et al., 2008). As a central organ for cholesterol 
metabolism (Schroepfer, 1981), liver synthesizes various lipoproteins involved in 
transporting cholesterol and other lipid metabolites throughout the body (Schaefer 












Figure 1. Homeostatic regulation of hepatic lipid metabolism. Signals from 
sites of lipid storage communicate the energy state of the body to the central 
nervous system, which also receives environmental inputs. The central nervous 
system integrates these signals and responds to control behavior, energy uptake, 
































1. De novo lipogenesis 
Excess energy supply beyond energy needs is converted into storage with 
various forms of lipid metabolites. Fatty acid synthesis and their further processes 
into phospholipids and triglycerides are referred as de novo lipogenesis. Any 
metabolite that yields acetyl-CoA is a potential supplier for lipogenesis. De novo 
lipogenesis is a complicated anabolic pathway that is composed of sequential 
processes. The first step of lipogenic reactions is the transportation of acetyl-CoA 
across the inner mitochondrial membrane into the cytoplasm and conversion of 
citrate to acetyl-CoA by ATP-citrate lyase (ACLY). The resulting acetyl-CoA is 
carboxylated to become malonyl-CoA by acetyl-CoA carboxylase (ACC), which is 
the key rate-limiting step for synthesis of fatty acid. Malonyl-CoA is further 
processed to generate long-chain fatty acids by fatty acid synthase (FASN). 
Following step is the desaturation of long-chain fatty acids catalyzed by stearoyl-
CoA desaturase (SCD). For instance, palmitic acid (C16:0) and stearic acid (C18:0) 
can be unsaturated to their respective monounsaturated forms palmitoleic acid 
(C16:1) and oleic acid (C18:1), which is catalyzed in endoplasmic reticulum (ER) 
membrane and provides fatty acids for phospholipid biosynthesis. And further 
acylation steps are mediated by several enzymes such as glycerol-3-phosphate 
acyltransferase (GPAT) and diacylglycerol acyltransferase (DGAT) to synthesize 
triglycerides (Karmen et al., 1963; Pearce, 1983). Further elongation and oxidation 
can occur in either mitochondrion or ER. 
 
2. Lipolysis and fatty acid oxidation 
Liver is also involved in lipid retrieval. The major source of lipids entering 
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to liver is free fatty acids released from adipose tissue and transported in systemic 
blood plasma complexed with albumin. Lipolysis is mainly catalyzed in cytosol 
and further processed in mitochondria. Triglycerides are hydrolyzed by several 
lipases including adipose tissue lipase (ATGL), hormone sensitive lipase (HSL), 
and monoacylglycerol lipase (MGL) (Jensen, 1997; Zechner et al., 2005). 
Hydrolyzed free fatty acids are transported into mitochondria through carnitine-
palmitoyl transferase (CPT). In the matrix of mitochondria, fatty acid β-oxidation 
is the catabolic process in which fatty acid molecules are broken down to generate 
acetyl-CoA, which enters the tricarboxylic acid (TCA) cycle. TCA cycle generates 
numerous biochemical energy sources including adenosine triphosphate (ATP), 
precursors of certain amino acids, and the reducing agent NADH that is used in 
numerous cellular reactions (Krebs, 1948). 
 
3. Lipid transport 
Lipid delivery is a key metabolic process for transportation of lipid 
metabolites via various lipoproteins in bloodstream. Most metabolic tissues 
facilitate lipid uptake to utilize lipids as energy sources. In intestine, transposable 
forms of lipids are converted into lipoprotein particles, which are water-soluble in 
bloodstream. There are five types of lipoproteins such as chylomicrons, very low-
density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density 
lipoprotein (LDL), and high-density lipoprotein (HDL). Chylomicrons are the 
largest lipoprotein produced in the intestine. Chylomicrons regulate transport of 
exogenous lipid metabolites into liver, heart, muscle, and adipose tissues, which is 
required for lipoprotein lipase (LPL). Both HDL and LDL contain high cholesterol 
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contents and play a key role in the regulation of cholesterol homeostasis. In 
contrast, both VLDL and IDL contain high triglyceride contents (Jackson et al., 
1976; Karmen et al., 1963). Each lipoprotein has a different subset of surface 
proteins which bind to corresponding surface receptors in target cells for delivering 
their contents. 
 
II. Hormonal and nutritional regulation of de novo lipogenesis 
De novo lipogenesis encompasses the processes of fatty acid synthesis and 
subsequent triglyceride synthesis, which are active in liver and adipose tissue. 
Lipogenic flux is tightly controlled by hormonal and nutritional changes (Girard et 
al., 1994; Kersten, 2001). During postprandial state, glucose increases lipogenesis 
by stimulating the release of insulin and inhibiting the release of glucagon from the 
pancreas. Insulin is the most important hormonal factor influencing lipogenesis. 
Insulin promotes lipogenesis by activating insulin downstream signaling cascades. 
In contrast, fasting reduces lipogenesis, which is accompanied with an increased 
rate of lipolysis. Thus, lipolysis eventually leads to net loss of triglycerides. Fasting 
is associated with significant changes in plasma hormone. For example, fasting 
decreases plasma insulin, while fasting increases plasma growth hormone and 
glucagon. Collectively, hormonal and nutritional changes are crucial factors to 
maintain energy homeostasis by regulating lipid metabolism in liver and adipose 
tissue. 
 
1. Transcriptional regulation of de novo lipogenesis 
During fasting-feeding cycle, most enzymes that are involved in de novo 
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lipogenesis are regulated at the transcriptional level. As an anabolic hormone, 
insulin transcriptionally activates most lipogenic pathway with transcription factors 
such as sterol regulatory element-binding protein 1c (SREBP1c) and liver X 
receptors (LXRs) (Farmer, 2006; Wang et al., 2015). In hepatocytes, 
overexpression of SREBP1c directly activates lipogenic genes such as FASN, ACC, 
and SCD1 even in the absence of insulin, whereas dominant-negative form of 
SREBP1c counteracts insulin-dependent induction of those genes. It has been well 
established that SREBP1c plays a critical role to activate lipogenic programming 
(Foretz et al., 1999; Kim and Spiegelman, 1996). In liver, overexpression of 
SREBP1c leads to increased hepatic lipid accumulation and insulin resistance 
(Shimano et al., 1997). In accordance with these, insulin-resistant obese animals 
with hepatic steatosis express elevated SREBP1c in liver (Ferre and Foufelle, 
2010). On the other hand, LXRs are member of nuclear receptor superfamily and 
are activated by oxysterols. Among two LXR isoforms, LXRα is abundantly 
expressed in lipogenic tissues such as liver and adipose tissue and it stimulates 
lipogenic gene expression by upregulating SREBP1c as a target gene (Janowski et 
al., 1996). LXRα deficient mice decreased expression of SREBP1c, FAS, ACC, and 
SCD1 (Kalaany et al., 2005). In addition, it has been shown that the effect of 
glucose on the expression of lipogenic genes is modulated by carbohydrate-
responsive element-binding protein (ChREBP) (Postic et al., 2007). In hepatocytes, 
activation of ChREBP in response to glucose results in the import of ChREBP into 
the nucleus where it binds to carbohydrate responsive elements (ChoREs). 
Although ChREBP activates a similar subset of genes of SREBP1c, ChREBP does 
not affect expression of SREBP1c. ChREBP deficient mice reduce basal and high-
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carbohydrate diet-stimulated hepatic expression of FASN, ACC, and L-PK (Ishii et 
al., 2004). Thus, these factors coordinately stimulate lipogenic gene expression in 
response to nutrients and hormones during feeding and fasting cycle (Table 1). 
 
2. Regulation of lipogenesis by hormonal and nutritional changes 
During postprandial state, insulin stimulates conversion of excess energy 
into triglycerides for long-term energy storage (Saltiel and Kahn, 2001). Insulin 
binds to the insulin receptor (IR) and activates phosphoinositide-3 kinase (PI3K) 
pathways through activating tyrosine kinase activity of IR. The activation of IR, 
insulin receptor substrates (IRSs), and PI3K leads to stimulate phosphoinositide-3-
dependent protein kinase 1 (PDK1), which in turn phosphorylates the 
serine/threonine kinase Akt/PKB (Taniguchi et al., 2006). Activated Akt/PKB 
phosphorylates several factors including mechanistic target of rapamycin (mTOR) 
and SREBP1c, which directly or indirectly mediate the effects of insulin on certain 
gene expression such as lipogenic pathways (Porstmann et al., 2008). On the 
contrary, during fasting state, glucose-producing system is activated in liver to 
supply glucose into the brain. The systemic adaptation to low glucose state is 
mediated by catabolic hormones such as glucagon, glucocorticoid s, and 
catecholamine, whereas it is counter-regulated by insulin (Jiang and Zhang, 2003). 
Glucagon, secreted from pancreatic α-cells under fasting conditions, binds to the 
membrane receptor coupled to GTP-binding proteins so that it induces intracellular 
cyclic adenosine monophosphate (cAMP) level, which in turn activates protein 
kinase A (PKA) pathways (Shabb, 2001). In hepatocytes, PKA phosphorylates 










Table 1. Lipogenic transcription factors and the types of modifications that 











Glucocorticoids, which are steroid hormones synthesized in the adrenal cortex, are 
released as part of acute stress response and mediate many metabolic actions. 
Similar to glucagon, glucocorticoids have an inhibitory effect of lipogenesis in 
adipose tissue (Leung and Munck, 1975). In addition, catecholamine is released 
from adrenal medulla as an adaptive response to emotional and physical stresses 
such as starvation and exercise. Catecholamine promotes catabolic metabolisms 
including lipolysis and fatty acid oxidation, whereas it represses anabolic lipid 
synthesis upon stress (Sharman, 1973). Nonetheless, the factors that are involved in 
SREBP1c suppression under fasting conditions are poorly understood. 
 
3. Hepatic lipid accumulation and NAFLD 
Non-alcoholic fatty liver disease (NAFLD) is associated with excessive 
lipid accumulation in hepatocytes and is the most common liver disease affecting 
10-30% of the general population. NAFLD encompasses a serial spectrum of 
conditions characterized by hepatic steatosis in individuals without significant 
alcohol consumption nor viral, congenital, and autoimmune liver disease markers 
(Cohen et al., 2011). NAFLD is resulted from an imbalance between lipid 
availability from de novo lipogenesis and lipid disposal via fatty acid oxidation or 
transport (Hebbard and George, 2011). In NAFLD, accumulated extra lipid often 
causes inflammation and eventually induces scar in liver. Thus, hepatic steatosis 
can progress to NASH (non-alcoholic steatohepatitis). Subsequently, NAFLD and 
NASH lead to development of cirrhosis and hepatocellular carcinoma (HCC). 
Furthermore, NAFLD is related to insulin resistance and metabolic syndromes. 
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III. Sterol regulatory element-binding proteins (SREBPs) 
SREBPs play key roles in lipid homeostasis from yeast to humans 
(Osborne, 2000). SREBP1c was cloned by the Spiegelman group as an adipocyte 
determination and differentiation-dependent factor 1 (ADD1) (Tontonoz et al., 1993) 
and was independently cloned by the Brown and Goldstein group as a member of 
SREBP transcription factor family, which are involved in cholesterol metabolism 
by binding to the sterol regulatory element in the promoter of LDL receptor (LDLR) 
gene (Wang et al., 1993). Since the members of SREBP family exhibit similar 
amino acid sequences and structures, they appear to share several molecular 
regulatory mechanisms to modulate their target genes (Horton et al., 2002). 
 
1. SREBP isoforms 
SREBPs belong to the basic helix-loop-helix-leucine zipper (bHLH-LZ) 
family of transcription factors. In mammals, three SREBP isoforms, including 
SREBP1a, SREBP1c (also known as ADD1), and SREBP2, are encoded by two 
genes (Horton et al., 2002). Both SREBP1a and SREBP1c are generated from a 
single SREBF1 gene through the use of alternative transcription start sites encoding 
different first exons that are spliced into a common second exon, designated 1a and 
1c, whereas SREBP2 is transcribed from a separate SREBF2 gene (Shimomura et 
al., 1997). SREBP1c mainly regulates fatty acid metabolism whereas SREBP2 
primarily controls cholesterol metabolism (Eberle et al., 2004b). 
Each SREBP precursor is composed of three functional domains; (i) a 
NH2-terminal domain that contains acidic transactivation domain and DNA binding 
domain, (ii) two hydrophobic transmembrane spanning domains interrupted by a 
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short loop that projects into the lumen of the ER, and (iii) a COOH-terminal 
domain that recruits regulatory protein complexes (Figure 2). Upon activation, ER 
anchored SREBP precursor proteins undergo complex proteolytic processes, 
leading to release the NH2-terminal active form of SREBPs (Yang et al., 2002). 
Subsequently, the NH2-terminal active form of SREBPs is translocated into the 
nucleus, where it stimulates target gene expression by binding to sterol response 
elements (SREs) or E-Box (CANNTG) in the promoter/enhancer regions of their 
own target genes (Amemiya-Kudo et al., 2000). While SREBP1a is highly 
expressed in most cultured cell lines, SREBP1c is predominantly expressed in 
metabolic tissues such as liver and adipose tissue (Shimomura et al., 1997). 
Overexpression of SREBP1c selectively promotes the expression of lipogenic 
genes, whereas deletion of SREBP1c leads to decrease expression of lipogenic 
enzymes (Liang et al., 2002). On the other hand, SREBP2 is responsible for 
cholesterol synthetic genes. Transgenic mice overexpressing SREBP2 shows 
preferential induction of genes involved in cholesterol biosynthesis (Horton et al., 
1998b). 
 
2. Nutritional control of SREBP1c 
SREBP1c is selectively regulated by several metabolic cues such as 
insulin and fasting/refeeding regimes in the liver, adipose tissue, and skeletal 
muscle (Bizeau et al., 2003; Horton et al., 1998a; Kim et al., 1998). During 
nutrient-rich conditions, insulin, which is released from pancreatic β-cells, 
stimulates the expression and activity of SREBP1c, leading to increase in de novo 












Figure 2. Domain structure of SREBP1c. SREBP1c controls lipid metabolism by 
regulating the expression of enzymes required for fatty acid synthesis. SREBP1c is 
synthetized as precursor forms bound to the endoplasmic reticulum membranes. 
Upon activation, the precursor undergoes a sequential two step cleavage process to 
































SREBP1c transcription, (ii) it stimulates post-translational modifications including 
proteolytic cleavage of SREBP1c from an inactive ER membrane-bound precursor 
to release the NH2-terminal active form, which is capable of translocating to the 
nucleus to promote target gene expression. Several studies have demonstrated that 
inhibition of PI3K by chemical inhibitors or expression of dominant-negative Akt 
inhibits ER-to-Golgi transport and proteolytic activation of SREBP1c (Du et al., 
2006). Since fasting/refeeding responses of lipogenic gene expression are severely 
blunted in SREBP1c deficient mice (Liang et al., 2002), SREBP1c has been 
considered as a key factor to mediate fatty acid metabolism upon nutritional 
changes. 
Under nutritionally deprived states, the expression of SREBP1c and 
lipogenic genes is suppressed by glucagon, which is secreted from pancreatic α-
cells. Activation of PKA and/or AMP-activated protein kinase (AMPK), results in 
decrease in SREBP1c expression, eventually leading to downregulate lipogenesis 
(Foretz et al., 1998; Zhou et al., 2001). Although SREBP1c-mediated lipogenic 
program is rapidly repressed by nutritional deprivations, it is largely unknown how 
SREBP1c and lipogenic programming might be shut down upon fasting. 
 
3. Post-translational regulation of SREBP1c 
The precursor of SREBP1c is retained in the ER membrane by SREBP 
cleavage-activating protein (SCAP) and insulin-induced gene (INSIG) proteins 
(Yang et al., 2002). Under the certain conditions such as depletion of 
phosphatidylcholine or polyunsaturated fatty acids, SCAP escorts the precursor of 
SREBP1c from the ER to the Golgi apparatus (Walker et al., 2011). The precursor 
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of SREBP1c is sequentially cleaved by certain proteases, translocating the mature 
form of SREBP1c into the nucleus (Sakai et al., 1998; Wang et al., 1994). It has 
been suggested that Akt and mechanistic target of rapamycin complex 1 (mTORC1) 
might be involved in SREBP1c processing upon insulin (Bakan and Laplante, 
2012). Akt-mediated SREBP1c phosphorylation increases the affinity of SCAP-
SREBP1c complex found on COPⅡ-coated vesicles, which accelerates the 
transport of SREBP1c to the Golgi, where SREBP1c can undergo proteolysis 
(Yellaturu et al., 2009). Also, mTORC1 and its downstream target kinases such as 
ribosomal protein S6 kinase β1 (S6K1) modulate SREBP1c processing upon 
insulin (Owen et al., 2012). In the nucleus, the activity and stability of mature 
SREBP1c appears to be regulated by several post-translational modifications such 
as phosphorylation, sumoylation, acetylation, and ubiquitination (Figure 3). For 
instance, SREBP1c is phosphorylated by glycogen synthase kinase 3 (GSK3), 
which is inactivated by Akt (Kim et al., 2004). In addition, SREBP1c is 
phosphorylated and repressed by PKA, resulting in decrease of the transcription of 
SREBP1c target genes (Lu and Shyy, 2006). SREBP1c is also modulated by the 
small ubiquitin-related modifier (SUMO)-1 (Hirano et al., 2003; Lee et al., 2014a). 
Besides, SREBP1c undergoes acetylation and deacetylation processes. SREBP1c is 
acetylated by p300/CREB-binding protein (CBP) under high glucose and insulin 
conditions (Naar et al., 1999), whereas SREBP1c is deacetylated by sirtuin 1 
(SIRT1). SIRT1-dependent deacetylation of SREBP1c inhibits its binding to its 
target gene promoters. Accordingly, deacetylation of SREBP1c promotes its 












Figure 3. Post-translational modifications of SREBP1c. Regulation of SREBP1c 
occurs at the level of SREBP1c expression, proteolytic processing, transcriptional 
activity, and post-translational modifications. Multiple signals regulate ER-to-
Golgi transport and the proteolytic activation of SREBP1c by controlling INSIG. 
SREBP1c is rapidly modulated by post-translational modifications, including 


























Together, it has been proposed that various post-translational modifications of 
SREBP1c appear to affect lipid metabolism upon nutritional and hormonal changes. 
 
IV. Lipid metabolism in cancer 
Cancer cells differ from normal cells in many aspects that allow them to 
abnormal cell growth and become invasive. Cancer cells undergo a complex 
metabolic reprogramming characterized by changes in anaerobic glycolysis and 
lipid synthetic processes (DeBerardinis et al., 2008; Schulze and Harris, 2012). The 
relevance of metabolic rearrangement of cancer cells has been included in the 
updated version of the review “Hallmarks of Cancer” where dysregulation of 
energy metabolism is included as one of emerging hallmarks (Hanahan and 
Weinberg, 2000, 2011). Tumorigenesis is dependent on the metabolic 
reprogramming as both direct and indirect consequences of oncogenic signaling 
(DeBerardinis et al., 2008). Cancer cells need to generate large amounts of 
precursors for macromolecule biosynthesis to allow the accumulation of cellular 
building blocks during cell growth and proliferation. Most cancer cells utilize 
aerobic glycolysis to support the production of intermediates for the synthesis of 
lipids, proteins and nucleic acids (Vander Heiden et al., 2009). In addition, cancer 
cells have increased glutamine uptake and glutaminolysis, which replenish 
intermediates of the TCA cycle that are redirected into biosynthetic reactions; a 
process known as anaplerosis (Hensley et al., 2013). The alterations in intracellular 
and extracellular metabolites that can accompany cancer-associated metabolic 
reprogramming have profound effects on gene expression, cellular differentiation, 
and the tumor microenvironment (Hsu and Sabatini, 2008). 
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1. Aberrant lipogenesis in cancer 
During tumorigenesis, lipids contribute to several aspects including tumor 
growth, energy and redox homeostasis, and metastasis. Certain cancer cells often 
show an increased de novo lipogenesis (Menendez and Lupu, 2007). Fatty acids are 
the major building blocks for the synthesis of phospholipids and triglycerides, 
which are mainly used for membrane biogenesis and energy storage, respectively 
(Bretscher and Raff, 1975; Divecha and Irvine, 1995). In cancer cells, most lipid 
metabolites are derived from de novo lipogenesis rather than from extracellular 
lipid uptake (Medes et al., 1953). Thus, increased lipogenesis provides the majority 
of lipids required for rapid proliferation of cancer cells. It has been reported that 
the shift from lipid uptake to de novo lipogenesis in cancer cells leads to increased 
membrane lipid saturation, resulting in higher levels of saturated and 
monounsaturated phospholipids, potentially protecting cancer cells from oxidative 
damage by reducing lipid peroxidation (Santos and Schulze, 2012). In addition, 
lipids are important signaling molecules in tumorigenesis (Spiegel et al., 1996). 
Some lipid metabolites are parts of paracrine hormones and growth factors, 
including prostaglandins, lyophosphatidic acid (LPA) or steroid hormones. Many 
studies have demonstrated that inhibition of several lipogenic enzymes such as 
FASN, ACC, and SCD1 can repress cancer cell growth (Currie et al., 2013). 
Although aberrant lipogenesis likely contributes to tumorigenesis in cancers, it has 





2. Hyperactivation of SREBP1c in metabolic disease and cancers 
It has been suggested that SREBP1c would be closely associated with type 
2 diabetes, insulin resistance, and pathogenesis of metabolic diseases (Shao and 
Espenshade, 2012). Accordingly, sequence variations at SREBF1 locus are linked 
to type 2 diabetes and increased expression of SREBP1c with genetic 
polymorphisms is associated with metabolic syndromes including cardiovascular 
diseases (Eberle et al., 2004a). Furthermore, hepatic SREBP1c is elevated in 
several animal models with insulin resistance and NAFLD (Marchesini et al., 2001; 
Muoio and Newgard, 2006). In addition, it has been reported that SREBP1c and its 
target genes are enhanced in certain cancers (Griffiths et al., 2013; Guo et al., 2014) 
and that SREBP1c promotes proliferation, migration, and invasion in glioblastoma 
and prostate cancers (Guo et al., 2009; Huang et al., 2012). On the other hand, it 
has been shown that inhibition of SREBP1c attenuates tumor growth in 
glioblastoma xenografts and that SREBP1c is defined a gene signature associated 
with poor survival in glioblastoma (Guo et al., 2009). Together, these findings 
imply that SREBP1c may play an important function in tumorigenesis, 
accompanied with lipid metabolism. 
 
V. Purpose of this study 
SREBP1c is tightly controlled by nutritional and hormonal changes to 
maintain whole-body energy homeostasis. To date, most studies have focused on 
the lipogenic roles of SREBP1c by coupling insulin action in metabolic organs. 
During postprandial states, insulin promotes SREBP1c activity to upregulate 
lipogenic programing. Conversely, hepatic SREBP1c is rapidly suppressed by 
22 
fasting signals to prevent futile lipogenic pathways. However, the molecular 
mechanisms that control SREBP1c turnover in response to nutritional deprivation 
are not thoroughly elucidated (Figure 4). Both animal models and human subjects 
with metabolic complications such as obesity, NAFLD, and certain cancers 
constitutively exhibit elevated SREBP1c. Thus, the elucidation of molecular 
mechanisms by which SREBP1c and lipogenic activity might be downregulated 
upon physiological cues appears to be important. Excess lipid accumulation is one 
of the hallmarks in clear cell renal cell carcinoma (ccRCC), the most common 
subtype of kidney cancers. To date, it has not been thoroughly understood the 
relationship between lipid metabolism and tumorigenesis in ccRCC. 
In this study, I have elucidated two novel findings for SREBP1c; (i) the 
suppression of SREBP1c during fasting and (ii) upregulation of SREBP1c in 
ccRCC. In the chapter one, to reveal which factors are involved in the inactivation 
of SREBP1c, I attempted to identify SREBP1c-interacting proteins by mass 
spectrometry analysis. I have identified that ring finger protein 20 (RNF20) is a 
novel E3 ubiquitin ligase for SREBP1c. Also, I have shown that RNF20-induced 
SREBP1c degradation downregulates hepatic lipid metabolism upon PKA 
activation. In the chapter two, I demonstrated that downregulation of RNF20 
stimulates tumorigenesis through SREBP1c activation in ccRCC. Moreover, in 
cultured ccRCC cells and xenograft models, RNF20 overexpression repressed 
lipogenesis and cell proliferation by inhibiting SREBP1c. To further explore which 
factors might be involved in SREBP1c-induced cell cycle progression in ccRCC, I 
tried to identify novel SREBP1c target genes, particularly, involving in cell cycle 











Figure 4. The unsolved question on the molecular mechanisms of SREBP1c 
suppression upon fasting. SREBP1c is a key transcription factor for de novo 
lipogenesis during the postprandial state. During nutritional deprivation, SREBP1c 
is rapidly suppressed by fasting signals to turn off lipogenic program. However, the 
molecular mechanisms that control SREBP1c activity in response to fasting status 




























novel target gene of SREBP1c and plays a crucial role in cell cycle control in 
ccRCC. Therefore, I would like to propose the idea that RNF20 would act as a 
tumor suppressor gene through inhibiting SREBP1c which modulates not only lipid 














Ring finger protein 20 regulates hepatic lipid metabolism 
through protein kinase A-dependent sterol regulatory 











SREBP1c is a key transcription factor for de novo lipogenesis during the 
postprandial state. During nutritional deprivations, hepatic SREBP1c is rapidly 
suppressed by fasting signals to prevent lipogenic pathways. However, the 
molecular mechanisms that control SREBP1c turnover in response to fasting status 
are not thoroughly understood. To elucidate which factors are involved in the 
inactivation of SREBP1c, I attempted to identify SREBP1c-interacting proteins by 
mass spectrometry analysis. As a result, RNF20 was identified as a novel E3 
ubiquitin ligase for SREBP1c. In this work, I reveal that RNF20 physically 
interacts with SREBP1c, leading to degradation of SREBP1c via ubiquitination. In 
accordance with these findings, RNF20 represses the transcriptional activity of 
SREBP1c and turns off the expression of lipogenic genes that are targets of 
SREBP1c. In contrast, knockdown of RNF20 stimulates the expression of 
SREBP1c and induces lipogenic activity in primary hepatocytes. Furthermore, 
activation of PKA with glucagon or forskolin enhances the expression of RNF20 
and potentiates the ubiquitination of SREBP1c via RNF20. In wild-type and db/db 
mice, adenoviral overexpression of RNF20 markedly suppresses FASN promoter 
activity and reduces the level of hepatic triglycerides, accompanied by a decrease 
in the hepatic lipogenic program. Taken together, these data suggest that RNF20 
acts as a negative regulator of hepatic fatty acid metabolism through degradation of 
SREBP1c upon PKA activation. Knowledge regarding this process enhances 





Sterol regulatory element-binding proteins (SREBPs) play key roles in 
lipid homeostasis from yeast to humans (Osborne, 2000; Tontonoz et al., 1993). In 
mammals, three different SREBP isoforms, including SREBP1a, SREBP1c (also 
known as ADD1), and SREBP2, are encoded by two genes: SREBF1 and SREBF2. 
SREBP1 regulates fatty acid metabolism, whereas SREBP2 controls cholesterol 
metabolism (Horton et al., 2002). When the cellular sterol level is low, SREBP 
cleavage-activating protein (SCAP) escorts the SREBP precursors from the 
endoplasmic reticulum (ER) to the Golgi, where SREBPs are cleaved by Site-1 and 
Site-2 proteases (Yang et al., 2002). Subsequently, the mature forms of SREBPs are 
translocated into the nucleus and stimulate the expression of target genes (Briggs et 
al., 1993; Wang et al., 1993). SREBP1a and SREBP1c are generated through 
transcription from alternative promoters and splicing from a single SREBF1 gene.  
In metabolic tissues such as adipose tissue and liver, SREBP1c is the 
predominant isoform of SREBP1 (Shimomura et al., 1997; Tontonoz et al., 1993). 
SREBP1c governs de novo lipogenesis by stimulating its target genes, including 
fatty acid synthase (FASN), acetyl-CoA carboxylase1 (ACC1), stearoyl-CoA 
desaturase1 (SCD1), and long-chain fatty acid elongase (ELOVL6) (Eberle et al., 
2004b; Kim and Spiegelman, 1996; Kumadaki et al., 2008). Furthermore, 
SREBP1c is sensitively regulated by nutritional and hormonal changes to achieve 
energy balance. For example, SREBP1c is suppressed by fasting, whereas 
SREBP1c is activated by feeding in adipose tissue and liver (Horton et al., 1998a; 
Kim et al., 1998). In parallel, the expression of most lipogenic genes, including 
FASN, ACC1, and SCD1, is also modulated in a fashion analogous to that of 
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nutritionally regulated SREBP1c (Foufelle et al., 1994; Girard et al., 1994; Kim et 
al., 1998). Accordingly, it has been reported that various hormones, such as insulin, 
glucagon, and adrenaline, participate in the regulation of SREBP1c and its target 
lipogenic genes (Foretz et al., 1999; Zhang et al., 2003). Insulin, a key postprandial 
hormone, stimulates the expression and activity of SREBP1c to accommodate 
anabolic processes, such as fatty acid synthesis, upon feeding (Flier and Hollenberg, 
1999; Kim et al., 1998). In contrast, glucagon, a key catabolic hormone, suppresses 
the activity of SREBP1c in fasting states, leading to a decrease in lipogenesis (Lu 
and Shyy, 2006). 
In the nucleus, mature SREBPs are very unstable and are rapidly degraded 
by the proteasome (Hirano et al., 2003; Hirano et al., 2001). Previous reports have 
shown that SREBP1 is phosphorylated by glycogen synthase kinase-3 beta (GSK-
3β), which leads to F-box- and WD repeat domain-containing 7 (FBXW7)-
dependent ubiquitination of SREBP1 (Punga et al., 2006; Sundqvist et al., 2005). 
However, a recent in vivo study revealed that inhibition of FBXW7 does not alter 
the expression of SREBP1c or lipogenic genes in the liver (Kumadaki et al., 2011). 
Although SREBP1c-mediated lipogenic program in liver is rapidly 
repressed by nutritional deprivations, the factors that are involved in the 
suppression of SREBP1c activity during fasting have not been thoroughly 
characterized. In this study, I demonstrate that ring finger protein 20 (RNF20) 
promotes polyubiquitination and degradation of SREBP1c. Overexpression of 
RNF20 represses SREBP1c activity, leading to a decrease in the expression of 
lipogenic genes. In obese db/db mice, RNF20 overexpression alleviates hepatic 
steatosis by reducing the lipogenic program via SREBP1c downregulation. 
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Furthermore, activated protein kinase A (PKA), a major signaling cascade that 
mediates the fasting state, induces degradation of SREBP1c by increasing RNF20 
expression. Taken together, these data suggest that RNF20 plays a critical role in 
the regulation of hepatic lipid metabolism by modulating the protein stability and 
transcriptional activity of SREBP1c during hormonal changes. 
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Materials and Methods 
Cell culture and reagents 
HEK293T, COS-1, and H4IIE cells were maintained in Dulbecco‟s 
modified Eagle‟s medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS, Gibco/BRL) and cultured at 37°C in a 5% CO2 incubator. Cycloheximide 
(CHX), H-89, insulin, T0901317 were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). Forskolin and MG132 were purchased from Calbiochem (San Diego, 
CA, USA). 
 
Plasmids and recombinant adenoviruses 
The nuclear form of SREBP1c, encoding amino acids 1–403 of rat 
SREBP1c, was cloned into the pcDNA3.1-Myc A plasmid (Invitrogen, Carlsbad, 
CA) and p3×FLAG-CMV-10 vector (Sigma-Aldrich). The full-length RNF20 
cDNA was cloned into the pcDNA3.1-Myc A and p3×FLAG-CMV-10 vectors. A 
small interfering RNA duplex for RNF20 was generated by GenePharma (Shanghai, 
China), and its target sequence was as follows: forward 5‟-
GGAGAGAGAACGAGAGAAA (dTdT)-3‟. The FASN-luciferase plasmid 
containing a –220 to +25 bp fragment of the FASN promoter ahead of a luciferase 
reporter gene was described previously (Kim et al., 1998). An RNF20-expressing 
adenovirus was generated through homologous recombination between a linearized 
transfer vector, pAd-Track, and the adenoviral vector pAd-Easy, as previously 
described (He et al., 1998). Ad-RNF20 contained the full-length murine RNF20 
cDNA with a C-terminal Myc-tag. An adenovirus encoding GFP only (Ad-Mock) 
was used as a control in all experiments. I produced adenoviruses in HEK293A 
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cells and purified them by CsCl gradient centrifugation, as described previously 
(Becker et al., 1994). Ad-FASN luc was generated based on FASN (–150/–43) 
luciferase as described (Dentin et al., 2007; Magana et al., 2000). 
 
Primary hepatocyte culture and infection with adenovirus 
Eight-week-old C57BL/6 male mice from Samtako (South Korea) were 
used for isolation of primary hepatocytes. After the animals were anesthetized, 
primary hepatocytes were isolated as previously described (Berry and Friend, 
1969). Briefly, total liver tissues were perfused with HBSS buffer (50 mM HEPES 
[pH 7.4], 5.5 mM glucose, 138 mM NaCl, 5.4 mM KCl, 4.17 mM NaHCO3, 0.34 
mM Na2HPO4 [dibasic], and 0.44 mM KH2PO4) into the portal vein. After 
perfusion, the liver tissues were dissociated into hepatocytes using collagenase 
buffer (HBSS buffer supplemented with 0.25% type IV collagenase (Sigma-
Aldrich) and 5 mM CaCl2). Subsequently, the isolated hepatocytes were washed 
with serum-free M199 medium (HyClone, South Logan, USA) and suspended in 
M199 medium supplemented with 10% FBS, 100 units/mL penicillin, and 100 
mg/mL streptomycin. Cell viability was assessed by the trypan blue exclusion test. 
Isolated hepatocytes were seeded at a density of 2.5×106 cells/dish in 100-mm 
tissue culture dishes and maintained at 37°C in 5% CO2. After cell attachment 
(approximately 4 hours), the culture media were replaced with fresh media. For 
adenoviral infections, hepatocytes were cultured for approximately 16 hours after 
cell attachment and subsequently incubated for 5 hours at 37°C in serum-free 
M199 either with or without adenovirus. Then, the culture media were replaced 
with fresh media, and the cells were incubated for 24 hours. 
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Flag affinity purification of the SREBP1c complex 
Adenoviruses encoding green fluorescent protein (GFP) or Flag-SREBP1c, 
which contains the transcriptionally active fragment of rat SREBP1c (amino acids 
1–403) fused with a Flag-tag, were used to infect primary hepatocytes. The 
infected hepatocytes were then gently washed with ice-cold phosphate-buffered 
saline (PBS) and lysed in hypotonic buffer (20 mM HEPES [pH 7.9], 1 mM EDTA, 
1 mM EGTA, 1 mM DTT, 0.5 mM PMSF, 0.2% Nonidet P-40 (NP-40), and 
protease inhibitor cocktail (Roche, Rotkreuz, Switzerland)). After incubation in 
hypotonic buffer for 10 minutes, the homogenates were centrifuged at 8,000 rpm 
for 1 minute at 4°C, and the supernatants (cytosolic fraction) were transferred to a 
fresh tube. The pellet was homogenized in ice-cold high salt buffer (10 mM 
HEPES [pH 7.9], 420 mM NaCl, 20% glycerol, 1 mM EDTA, 1 mM EGTA, 1 mM 
DTT, 0.5 mM PMSF, and protease inhibitor cocktail) on a rotating shaker for 30 
minutes at 4°C and subsequently centrifuged at 12,000 rpm for 15 minutes at 4°C. 
Consequently, the supernatants (nuclear fraction) were incubated with anti-Flag 
M2-agarose affinity gel (Sigma-Aldrich) for 2 hours at 4°C on a rotating shaker. 
The beads were then rinsed four times for 10 minutes each in washing buffer (20 
mM HEPES [pH 7.9], 150 mM NaCl, 0.5 mM EDTA, 0.5 mM PMSF, 1% Triton 
X-100, and protease inhibitor cocktail), followed by elution with sodium dodecyl 
sulfate (SDS) buffer (250 mM Tris-HCl [pH 6.6], 10% SDS, 50% glycerol, 500 





GST pull-down assay 
GST pull-down assays were performed as previously described (Lee et al., 
2003). Briefly, GST and GST-SREBP1c recombinant proteins were bound to 
glutathione beads and incubated with 35S-Met-labeled RNF20 protein. The beads 
were washed with Tris-buffered saline containing 0.1% Tween-20 (TBST, 25 mM 
Tris-HCl [pH 8.0], 137 mM NaCl, 2.7 mM KCl, and 0.1% Tween-20) and 
analyzed by autoradiography after SDS-PAGE. 
 
Western blot analysis 
The cells were lysed on ice with modified radioimmunoprecipitation assay 
(RIPA) buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1 mM EDTA, 1 mM 
PMSF, 1% NP-40, 0.25% Na-deoxycholate, and protease inhibitor cocktail) and 
subjected to immunoprecipitation or western blotting analyses. For 
immunoprecipitation, equal amounts of the total cell extracts were incubated with 
Myc or Flag antibody, and the immunoprecipitated complexes were collected using 
protein A-sepharose beads (GE Healthcare, UK). Further, the pellets were washed 
extensively and subjected to western blotting analyses according to previously 
described protocols (Kim et al., 2009). The following antibodies were used in the 
western blotting analyses: RNF20 (Abcam, MA; #ab32629; 1:1,000), FASN (Cell 
Signaling, MA; #3180; 1:1,000), GAPDH (AbFrontier, South Korea; #LF-PA0018; 
1:1,000), Pol II (Santa Cruz Biotechnology, CA; #SC-5943; 1:1,000), Lamin B1 
(Abcam; #ab16048; 1:1,000), β-actin (Sigma-Aldrich; #A5316; 1:2,000), Flag-tag 
(Sigma-Aldrich; #F1804; 1:1,000), Myc-tag (Cell Signaling; #2276; 1:1,000) and 
HA-tag (Covance Research, PA; #16B12; 1:1,000). SREBP1 antibodies were 
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produced by AbFrontier using the nuclear form of recombinant SREBP1 as an 
immunogen. Relative amounts of each protein were calculated using ImageJ 
software. 
 
Cell-based ubiquitination assay 
COS-1 cells were transfected with plasmids encoding Myc-SREBP1c, 
Flag-RNF20 and HA-ubiquitin in the presence or absence of forskolin (20 μM). 
After transfection for 36 hours, the cells were incubated with MG132 (10 μM) for 
12 hours and lysed with cold RIPA buffer. Equal amounts of total cell lysates were 
incubated with the Myc antibodies for 2 hours at 4°C. Immunocomplexes were 
collected using protein-A sepharose beads for 1 hour at 4°C. Further, the 
immunoprecipitates were washed with RIPA buffer and subjected to SDS-PAGE 
followed by western blotting analyses with anti-HA antibodies. 
 
Transient transfection and luciferase assay 
HEK293T cells were transiently transfected with several DNA constructs 
according to the calcium-phosphate method described previously (Seo et al., 
2004a). After incubation for 24 hours, transfected cells were harvested and assayed 
for luciferase and β-galactosidase activity. Total cell extracts were prepared with 
lysis buffer (25 mM Tris-phosphate [pH 7.8], 10% glycerol, 2 mM CDTA, 2 mM 
DTT, and 1% Triton X-100), and the activities of luciferase and β-galactosidase 
were measured according to the manufacturer‟s instructions (Promega). The 
relative luciferase activity was normalized to β-galactosidase activity in each 
sample. Transfections of SREBP1c, RNF20 and the siRNA duplex for RNF20 into 
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COS-1 and mouse primary hepatocytes were carried out with 




Flag-tagged nuclear SREBP1c and Myc-tagged RNF20 plasmids were co-
transfected into HeLa cells cultured in a 6-well plate. After transfection for 24 
hours, the cells were rinsed with PBS and fixed in 4% paraformaldehyde for 10 
minutes. The fixed cells were incubated with 0.5% Triton X-100-PBS for 5 
minutes and 3% bovine serum albumin (BSA)-PBS for 1 hour. The cells were then 
incubated with anti-Flag (Sigma-Aldrich; #F1804; 1:200) and anti-Myc (Cell 
Signaling; #2276; 1:200) antibodies at 4°C overnight followed by incubation with 
fluorophore-conjugated secondary antibodies (1:200) for 1 hour in the dark at room 
temperature. All images were recorded and processed under equivalent conditions. 
 
Oil Red O staining 
To assess intracellular lipid accumulation, hepatocytes were fixed with 10% 
formaldehyde (Merck, Germany) in PBS and stained with Oil Red O as described 
previously (Kim et al., 2010). Mouse primary hepatocytes were transfected with 
siRNA targeted against RNF20 in M199 medium. After 48 hours, the transfected 
cells were washed twice with PBS, fixed for 1 hour with 3.7% formaldehyde in 
PBS and subsequently dehydrated with 100% propylene glycol (AMRESCO, USA) 
for 5 minutes. After removing the propylene glycol, Oil Red O dye was added to 
the plate and incubated overnight. Subsequently, Oil Red O was removed, and 85% 
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propylene glycol was added to the plate, which was allowed to stand for 5 minutes. 
Finally, excess dye was washed away with distilled water until the background was 
clear. To detect hepatic lipid contents in liver section, OCT compound-embedded, 
snap-frozen liver tissues were fixed and stained with Oil Red O. Images were 
obtained using an EVOS®  ORIGINAL microscope (Advanced Microscopy Group) 
and a Nikon TMS inverted microscope. 
 
RNA isolation and quantitative RT-PCR 
Cell As described previously (Jeong et al., 2010), total RNA was isolated 
with TRIzol reagent (Molecular Research Center, OH, USA), and cDNA was 
synthesized with M-MuLV reverse transcriptase (Fermentas, MD, USA). qRT-
PCR analyses were performed with the MyiQ quantitative real-time PCR detection 
system (Bio-Rad Laboratories, CA, USA) using SYBR Green I (BioWhittaker 
Molecular Applications). The relative levels of each mRNA were normalized to the 
levels of TBP, GAPDH, or cyclophilin mRNA. The qRT-PCR primers used in this 
study were synthesized by Bioneer, and the primer sequences are listed in Table 2. 
 
Animals 
All animal experiments were approved by the Seoul National University 
Animal Experiment Ethics Committee. Male C57BL/6 mice were obtained from 
Samtako (South Korea), and db/db mice were obtained from Central Lab (South 
Korea). The animals were housed in colony cages in 12 hours light/12 hours dark 
cycles. Standard chow (Purina Mills) was given ad libitum. 
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Table 2. Primers sequences for qRT-PCR 
Species Gene Sequence (5’ to 3’) Direction 
Mouse 

































































In vivo imaging system 
Ten-week-old C57BL/6 mice and nine-week-old db/db mice were injected 
through the tail vein with adenoviruses encoding GFP (Ad-Mock), RNF20 (Ad-
RNF20) and FASN luciferase (Ad-FASN-luc). After 7 days, adenovirus-infected 
mice were injected intraperitoneally with 100 mg/kg sterile D-luciferin. The mice 
were then anaesthetized with Zoletil®  and imaged using the IVISTM 100 Imaging 
System (Xenogen) as described previously (Dentin et al., 2007). 
 
Oral glucose tolerance test 
For the oral glucose tolerance test, db/db mice were fasted for 12 hours 
and basal blood samples were taken, followed by oral glucose administration (1.5 
g/kg of body weight). Blood samples were drawn at 15, 30, 45, 60, and 90 minutes 
after administration. 
 
Hepatic triglyceride analysis 
Hepatic triglycerides were measured in cell lysates using a colorimetric 
assay and expressed as μg of lipid per mg of cellular protein as described 
previously (Jo et al., 2013). In brief, liver tissue samples were homogenized in 5% 
Triton X-100, and total tissue extracts were incubated in a water bath at 80°C and 
subsequently cooled down to room temperature twice. After centrifugation at 
12,000 rpm for 5 minutes at room temperature, the supernatant was collected and 
used in triglyceride assays. Measurement of hepatic triglycerides was performed 




All observed data are presented as the mean ± standard deviation (SD). 
Error bars represent SD, and P values were calculated by Student‟s t test. The SD 




SREBP1c is decreased by ubiquitination upon PKA activation. 
Ectopic SREBP1c is tightly regulated by hormonal and nutritional changes 
to reflect the energy status (Foretz et al., 1999; Zhang et al., 2003). When I 
examined the protein stability of SREBP1c in the presence of cycloheximide, an 
inhibitor of protein synthesis, the degradation rate of nuclear SREBP1c was 
reduced in the presence of MG132, an inhibitor of the 26S proteasome (Figures 5A 
and 5B), indicating that the rapid turnover of SREBP1c protein might be mediated 
by proteasomal degradation. Although it has been demonstrated that the 
cAMP/PKA pathway is involved in the suppression of SREBP1c (Lu and Shyy, 
2006; Yamamoto et al., 2007; Yellaturu et al., 2005), it is largely unknown how 
PKA affects SREBP1c protein stability. To address this issue, primary hepatocytes 
were treated with forskolin, an activator of the PKA cascade. The level of SREBP1 
protein was reduced by forskolin (Figures 5C and 5D), while that of SREBP1 
protein was restored by MG132 in a dose-dependent manner (Figures 6A and 6B), 
implying that PKA would be involved in the regulation of SREBP1c protein 
stability through the ubiquitin-proteasome system. Next, to investigate whether 
SREBP1c is indeed ubiquitinated by PKA activation, cell-based ubiquitination 
assays were carried out. As shown in Figure 6C, forskolin efficiently 
polyubiquitinated the SREBP1c protein, while H-89, the inhibitor of PKA, greatly 
attenuated forskolin-induced SREBP1c ubiquitination. Therefore, these data 







Figure 5. PKA activation decreases SREBP1c protein stability. (A) Mouse 
primary hepatocytes were treated with cycloheximide (20 μM) for the indicated 
periods with or without MG132 (20 μM) treatment for 3 hours. After the 
preparation of nuclear extracts, western blotting analyses were performed with the 
indicated antibodies. DMSO, dimethyl sulfoxide; CHX, cycloheximide; nSREBP1, 
nuclear SREBP1. (B) Quantification of the amounts of nSREBP1 protein in the 
presence of MG132 in Figure 5A. Relative level of nSREBP1 protein was 
calculated by ImageJ software and normalized with Pol II using nonlinear 
regression curve fitTM program (GraphPad Prism). The level of nSREBP1 protein at 
time zero in each condition was normalized to 100%. (C) Mouse primary 
hepatocytes were treated with forskolin (50 μM) for 6 hours and harvested at the 
indicated time points after cycloheximide (50 μM) treatment. After isolating 
nuclear extracts, western blotting analyses were performed with the indicated 
antibodies. (D) Quantification of the amounts of nSREBP1 protein in the presence 
of forskolin in Figure 5C. Relative level of nSREBP1 protein was calculated by 
ImageJ software and normalized with Lamin B1 using nonlinear regression curve 
fitTM program (GraphPad Prism). The level of nSREBP1 protein at time zero in 




































Figure 6. SREBP1c is decreased by ubiquitination upon PKA activation.    
(A) Mouse primary hepatocytes were treated with or without forskolin (50 μM) in 
the presence of MG132 with indicated dose for 4 hours. Nuclear extracts were 
isolated and analyzed by western blotting analyses with the indicated antibodies.  
(B) Quantification of the amounts of nSREBP1 protein in Figure 6A. Relative level 
of nSREBP1 protein was calculated by ImageJ software and normalized with 
Lamin B1. The level of nSREBP1 protein without MG132 and forskolin was 
normalized to 100%. (C) COS-1 cells were co-transfected with plasmids encoding 
Myc-SREBP1c and HA-ubiquitin. After transfection, the cells were treated with 
MG132 (10 μM) for 12 hours and subsequently pretreated with H-89 (20 μM) for  
1 hour. Then, the cells were treated with or without forskolin (20 μM) for another  
3 hours. Total cell lysates were subjected to co-immunoprecipitation with anti-Myc 
antibody, followed by western blotting analyses with the indicated antibodies. IP, 
immunoprecipitation; IB, immunoblotting; IgG, immunoglobulin G. All 
experiments were repeated independently at least three times, and representative 

































RNF20 physically interacts with SREBP1c. 
To investigate which factors are involved in the degradation and 
ubiquitination of nuclear SREBP1c protein, I attempted to identify SREBP1c-
interacting proteins; particularly, I was eager to identify an E3 ubiquitin ligase. 
Mouse primary hepatocytes were infected with adenovirus expressing nuclear 
SREBP1c, and affinity purifications were conducted. Mass spectrometry analyses 
indicated that RNF20 (also known as BRE1A) was a potential SREBP1c-
interacting protein (Figures 7A and 7B). To validate the physical interaction 
between RNF20 and SREBP1c, GST pull-down assays were performed. Because 
SREBP1c forms homodimers, 35S-Met labeled SREBP1c was used as a positive 
control (Figure 8A, lane 5). RNF20 protein was detected in the fractions eluted 
from the GST-SREBP1c protein complex (Figure 8A, lane 6). Further, when I 
biochemically tested the physical interaction between RNF20 and SREBP1c, 
RNF20 was co-immunoprecipitated with SREBP1c (Figure 8B), indicating that 
RNF20 could physically interact with SREBP1c. Moreover, I observed that 
endogenous RNF20 formed immuno-complex with endogenous SREBP1 in liver 
nuclear extracts (Figure 8C). In parallel immunocytochemistry experiments, 
exogenous Flag-SREBP1c and Myc-RNF20 proteins co-localized in the nucleus 
(Figure 8D), implying that RNF20 can interact with SREBP1c in the nucleus. 
 
RNF20 promotes ubiquitination and degradation of SREBP1c. 
Given that the E3 ubiquitin ligase RNF20 associates with SREBP1c, the 
effect of RNF20 on SREBP1c stability was examined. As shown in Figure 9A, the 











Figure 7. Nuclear SREBP1c interacting proteins are identified by using 
affinity purification. (A) Mouse primary hepatocytes were infected with 
adenovirus expressing either GFP alone (Mock) or Flag-tagged nuclear SREBP1c 
(Flag-SREBP1c). Nuclear extracts were subjected to flag affinity purification 
followed by SDS-PAGE. After affinity purification, SREBP1c interacting candidate 
proteins were visualized by silver staining. (B) The list of nuclear SREBP1c 










































Figure 8. RNF20 physically interacts with SREBP1c. (A) GST pull-down assays 
were performed as described in “Materials and Methods”. Inputs of in vitro-
translated 35S-Met-labeled SREBP1c (nuclear form) and RNF20 are shown in lanes 
1 and 2, respectively. Radioisotope-labeled proteins were mixed with GST or GST-
SREBP1c recombinant proteins, and GST pull-down analyses were performed. 
GST, glutathione S-transferase. (B) HEK293T cells were transiently co-transfected 
with Flag-SREBP1c and/or Myc-RNF20 expression vectors. After preparing total 
cell lysates, co-immunoprecipitation with anti-Flag antibody and western blotting 
analyses were performed with the indicated antibodies. IP, immunoprecipitation; IB, 
immunoblotting; IgG, immunoglobulin G. (C) Nuclear extracts were isolated from 
mouse livers and subsequently co-immunoprecipitated with IgG or the indicated 
antibody. Immuno-protein complexes were detected by western blotting analyses 
with the indicated antibodies. nSREBP1, nuclear SREBP1. (D) Immuno-
cytochemistry analyses of co-expressed Flag-SREBP1c and Myc-RNF20 in HeLa 



































Moreover, the RNF20-induced reduction of SREBP1c protein was alleviated by 
MG132 (Figure 9A, lane 6), indicating that RNF20 would stimulate SREBP1c 
degradation via ubiquitin-proteasomal degradation. Consistent with these data, 
cycloheximide-chase assays revealed that the half-life of SREBP1c was shortened 
by ectopic expression of RNF20 (Figure 9B). Next, as RNF20 exhibits E3 ubiquitin 
ligase activity, I tested whether SREBP1c is ubiquitinated by RNF20. As shown in 
Figure 10A, RNF20 greatly promoted the level of SREBP1c polyubiquitination. To 
confirm whether endogenous RNF20 plays a role in SREBP1c ubiquitination, I 
investigated the effect of RNF20 knockdown via siRNA on the ubiquitination of 
SREBP1c. I found that suppression of RNF20 relieved the level of SREBP1c 
polyubiquitination (Figure 10B). These data indicate that RNF20 can act as an E3 
ubiquitin ligase for SREBP1c and can accelerate polyubiquitination and 
degradation of SREBP1c protein. 
 
RNF20 suppresses the transcriptional activity of SREBP1c. 
To understand the biological significance of SREBP1c degradation by 
RNF20, I investigated the transcriptional activity of SREBP1c with or without 
RNF20 overexpression. Consistent with previous reports (Kim et al., 1998; Seo et 
al., 2004b), SREBP1c transactivated the promoters of FASN and adiponectin 
(Acrp30) genes, whereas coexpression with RNF20 suppressed the transcriptional 
activity of SREBP1c (Figure 11A). When the level of SREBP1 protein was 
investigated with or without RNF20 overexpression in primary hepatocytes, 
RNF20 overexpression clearly decreased in endogenous and ectopic nuclear 










Figure 9. RNF20 represses the protein stability of SREBP1c. (A) HEK293T 
cells transfected with Flag-SREBP1c and/or Myc-RNF20 expression vectors were 
incubated with or without MG132 (20 μM) for 4 hours, and total cell lysates were 
subjected to SDS-PAGE followed by western blotting analyses with the indicated 
antibodies. (B) COS-1 cells transfected with Myc-SREBP1c and/or Myc-RNF20 
expression vectors were harvested at 0, 2, 4, and 8 hours after cycloheximide 
treatment (30 μM). After isolating total cell lysates, western blotting analyses were 











































Figure 10. RNF20 mediates ubiquitination and degradation of SREBP1c.   
(A) COS-1 cells were co-transfected with Myc-SREBP1c, HA-tagged ubiquitin 
and/or Flag-RNF20 expression vectors. After incubation for 36 hours, the cells 
were treated with MG132 (10 μM) for 12 hours. Total cell lysates were isolated and 
subjected to cell-based ubiquitination assays. IP, immunoprecipitation; IB, 
immunoblotting; IgG, immunoglobulin G. (B) COS-1 cells were transfected with 
non-specific control siRNA (siControl) or RNF20-specific siRNA (siRNF20). After 
incubation for 36 hours, the cells were incubated with MG132 (10 μM) for      
12 hours. Total cell lysates were isolated and subjected to cell-based ubiquitination 




































elevated endogenous SREBP1 protein in the presence of insulin and/or T0901317, 
a LXR agonist (Figure 11C). Next, to address the question whether RNF20 could 
affect the expression of SREBP1c target genes, I analyzed the mRNA levels of its 
target genes in RNF20 and/or SREBP1c-overexpressing hepatocytes. In primary 
hepatocytes, RNF20 overexpression alone significantly decreased many lipogenic 
genes including SREBP1c, FASN, SCD1, ACC1, and ELOVL6 (Figure 12A, lane 2). 
Consistent with previous reports (Horton et al., 2002; Kim et al., 1998), SREBP1c 
elevated the mRNA expression of lipogenic genes such as FASN, SCD1, and 
ELOVL6 in primary hepatocytes (Figure 12A, lane 3). However, the effects of 
RNF20 overexpression on lipogenic suppression were marginal in SREBP1c-
overexpressing hepatocytes (Figure 12A, lane 4). It is feasible to speculate that 
high level of SREBP1c protein may partly stimulate lipogenic gene expression 
even in the presence of RNF20 overexpression. On the other hand, overexpression 
of RNF20 did not significantly alter the mRNA level of other SREBP isoforms, 
including SREBP1a and 2 (Figure 12A). Moreover, in primary hepatocytes, RNF20 
overexpression decreased intracellular lipid accumulation as determined by Oil 
Red O staining (Figure 12B). These data indicate that RNF20 can indeed 
downregulate lipogenic gene expression by suppressing SREBP1c. 
 
Suppression of RNF20 enhances hepatic lipid metabolism via SREBP1c. 
To determine whether endogenous RNF20 influences lipogenic activity, I 
investigated the effect of RNF20 suppression via siRNA on lipogenic gene 
expression in primary hepatocytes. When the level of RNF20 was decreased (by 





Figure 11. RNF20 suppresses the transcriptional activity of SREBP1c.      
(A) HEK293T cells were co-transfected with luciferase reporter plasmids 
containing the FASN or Acrp30 promoter along with pRSV-β-gal, Myc-SREBP1c 
and/or Myc-RNF20 expression vectors. Total cell lysates were subjected to 
luciferase and β-galactosidase assays. The values presented are representative data 
from three independent experiments carried out in triplicate. Each bar represents 
the mean ± SD of three individual samples. #P < 0.05 vs. negative control; ##P < 
0.01 vs. negative control; *P < 0.05; RLU, relative luminescence units. (B) Mouse 
primary hepatocytes were infected with adenovirus containing GFP alone (Ad-
Mock), Flag-SREBP1c (Ad-SREBP1c) and/or Myc-RNF20 (Ad-RNF20) as 
indicated. After infection for 12 hours, total cell lysates were subjected to SDS-
PAGE followed by western blotting analyses with the indicated antibodies. 
nSREBP1, nuclear SREBP1. (C) Mouse primary hepatocytes were infected with 
Ad-Mock or Ad-RNF20 for 12 hours. Subsequently, the culture media were 
replaced with fresh media and 24 hours. And then the cells were incubated for   
12 hours with or without insulin (100 nM) and T0901317 (3 μM). Total cell lysates 
were subjected to SDS-PAGE followed by western blotting analyses with the 







































Figure 12. RNF20 downregulates the expression of SREBP1c and its target 
genes. (A) Mouse primary hepatocytes were infected with Ad-SREBP1c and/or 
Ad-RNF20. After infection for 12 hours, the culture media were replaced with 
fresh media and subsequently incubated for 36 hours. The relative mRNA levels 
were measured using qRT-PCR. The relative values were normalized to the level of 
GAPDH mRNA. Each bar represents the mean ± SD of three individual samples. 
#P < 0.05 vs. negative control; ##P < 0.01 vs. negative control; *P < 0.05;      
**P < 0.01. (B) Mouse primary hepatocytes were transduced with Ad-SREBP1c 
and/or Ad-RNF20 adenoviruses. After incubation for 48 hours, intracellular lipid 
droplets were visualized by Oil Red O staining, and the cells were photographed. 




































FASN and ELOVL6, were significantly elevated (Figure 13A). On the contrary, the 
mRNA levels of other SREBP isoforms, including SREBP1a and 2, were not 
altered by RNF20 suppression (Figure 13A), whereas the level of SREBP1c mRNA 
was upregulated, probably, through an auto-regulatory mechanism (Amemiya-
Kudo et al., 2000; Dif et al., 2006). Consistently, suppression of RNF20 with 
siRNA in primary hepatocytes increased the level of endogenous SREBP1 protein 
(both precursor and nuclear forms) (Figure 13B) and promoted intracellular neutral 
lipid accumulation as determined by Oil Red O staining (Figure 14A). Additionally, 
RNF20-suppressed hepatocytes stored more intracellular cellular triglycerides than 
control primary hepatocytes (Figure 14B). On the contrary, the mRNA expression 
levels of other lipogenic transcription factors, such as peroxisome proliferator-
activated receptor-gamma (PPARγ), liver X receptor-alpha (LXRα), and 
carbohydrate responsive element-binding protein (ChREBP), were not altered by 
RNF20 suppression (Figure 13A and 14C). Besides, the mRNA levels of fatty acid 
oxidation pathway genes, including peroxisome proliferator-activated receptor-
alpha (PPARα), carnitine palmitoyltransferase 1A (CPT1A), medium-chain acyl-
CoA dehydrogenase (MCAD) and aconitase 1 (ACO1), were not changed by 
RNF20 suppression in primary hepatocytes (Figure 14C), implying that RNF20 can 
selectively downregulate lipogenic gene expression via SREBP1c in hepatocytes. 
 
Hepatic RNF20 is regulated by nutritional changes. 
Nutritional and hormonal changes coordinate energy homeostasis, 
including lipid and glucose metabolism. Thus, I examined whether the nutritional 








Figure 13. Suppression of RNF20 enhances hepatic lipid metabolism via 
SREBP1c. (A) Mouse primary hepatocytes were transfected with siControl or 
siRNF20, and relative mRNA levels were determined using qRT-PCR. The level of 
each mRNA was normalized to the mRNA level of the TATA-binding protein 
(TBP) gene. Each bar represents the mean ± SD of three individual samples.    
*P < 0.05 and **P < 0.01 were considered significant. SQS, squalene synthetase; 
LDLR, low-density lipoprotein receptor. (B) Mouse primary hepatocytes were 
transfected with siControl or siRNF20. After isolating nuclear extracts, western 
blotting analyses were performed with the indicated antibodies. Relative amounts 
of RNF20 and nuclear SREBP1 proteins were calculated using Labworks software 
(UVP Bioimaging System) and normalized to Lamin B1. The western blots shown 
are representative of three independent experiments. pSREBP1, precursor SREBP1; 











































Figure 14. RNF20 negatively regulates hepatic lipogenesis. (A) Mouse primary 
hepatocytes were transfected with siControl or siRNF20. After incubation for    
48 hours, intracellular lipid droplets were visualized by Oil Red O staining, and the 
cells were photographed. Microscopic views of cells at a magnification of ×200 are 
shown. Scale bar, 100 μm. (B) Intracellular triglyceride contents were measured 
biochemically. (C) Mouse primary hepatocytes were transfected with siControl or 
siRNF20. Relative mRNA levels of PPARα, ChREBP and their target genes were 
determined using qRT-PCR. The level of each mRNA was normalized to the 






































expression of RNF20 mRNA was significantly increased (Figure 15A), whereas 
that of SREBP1c and FASN mRNA was decreased. These observations indicate 
that the change in RNF20 expression might be associated with the regulation of 
SREBP1c during nutritional changes. In contrast, the mRNA level of FBXW7, an 
E3 ligase of SREBP proteins, was unchanged by either feeding or fasting 
conditions (Figure 15A). Upon fasting, glucagon stimulates the PKA cascade to 
regulate lipid and glucose metabolism to accomplish catabolic responses (Girard et 
al., 1994; Jitrapakdee, 2012). Thus, to address the question of whether RNF20 
expression might be regulated by PKA activation, I examined the level of RNF20 
mRNA in hepatocytes with or without forskolin. Notably, forskolin increased the 
level of RNF20 mRNA, whereas it decreased SREBP1c and SCD1 mRNA levels 
(Figure 15B). Furthermore, in primary hepatocytes, both glucagon and forskolin 
increased the RNF20 protein level and decreased the nuclear SREBP1 protein level 
(Figure 15C). Next, to determine whether cytosolic or nuclear RNF20 is regulated 
upon PKA activation, cytosolic and nuclear extracts were isolated from hepatoma 
cells with or without forskolin treatment. As shown in Figure 15D, forskolin 
enhanced the nuclear RNF20 protein level and reduced the nuclear SREBP1 
protein level. However, unlike RNF20, FBXW7 expression was not altered by 
forskolin (Figure 15B). In addition, I investigated the mRNA levels of SREBP1c 
target genes in RNF20-suppressed hepatocytes treated with forskolin. As shown in 
Figure 16A, the mRNA levels of lipogenic genes such as SREBP1c, FASN, and 
SCD1 were decreased by forskolin, whereas RNF20 suppression via siRNA 
restored the expression of lipogenic genes, even in the presence of forskolin 





Figure 15. Expression of hepatic RNF20 is nutritionally regulated. (A) The 
levels of each mRNA in the livers of fed and fasted mice were determined by qRT-
PCR analysis. The TBP mRNA level was used for normalization. The fed control 
(Fed) was allowed free access to food, and the fasted groups (Fast) were denied 
access to food for 24 hours. The refed group (Refed) was allowed free access to 
food for 7 hours after 24 hours of fasting. n = 4 for each group. *P < 0.05 and **P 
< 0.01 were considered significant. (B) Mouse primary hepatocytes were incubated 
with or without forskolin (+ indicates 10 µM forskolin and ++ indicates 100 µM 
forskolin) for 6 hours. Each relative mRNA level was determined using qRT-PCR 
and normalized to the TBP mRNA level. As a positive control, the expression of 
G6Pase mRNA was greatly enhanced by forskolin. Each bar represents the mean ± 
SD of three individual samples. *P < 0.05 and **P < 0.01 were considered 
significant. N.D., not detected. (C) Mouse primary hepatocytes were incubated 
with glucagon (100 nM) or forskolin (50 μM) for 4 hours. Total cell lysates were 
subjected to western blotting analyses with the indicated antibodies. nSREBP1, 
nuclear SREBP1. (D) H4IIE rat hepatoma cells were incubated with forskolin (50 
μM) for 5 hours. Cytosolic and nuclear extracts were subjected to western blotting 







































Figure 16. RNF20 is a negative regulator of SREBP1c and the lipogenic 
program upon PKA activation. (A) Mouse primary hepatocytes transfected with 
siControl or siRNF20 were incubated with forskolin (10 μM) for 6 hours. The level 
of each mRNA was determined using qRT-PCR and normalized to the TBP mRNA 
level. Each bar represents the mean ± SD of experiments carried out in triplicate. 
*P < 0.05 and **P < 0.01 were considered significant. (B) COS-1 cells were co-
transfected with DNA plasmids and siRNAs as indicated. After incubation for   
36 hours, the cells were incubated with MG132 (10 μM) for 12 hours and 
subsequently treated with forskolin (20 μM) for 4 hours. Then, the cells were 
treated with or without forskolin (20 μM) for another 3 hours. Total cell lysates 
were isolated and subjected to cell-based ubiquitination assays. IP, 



































SREBP1c ubiquitination, I examined the level of SREBP1c ubiquitination upon 
PKA activation with RNF20 suppression. As shown in Figure 16B, knockdown of 
RNF20 with siRNA successfully decreased the level of PKA-mediated SREBP1c 
ubiquitination, implying that PKA-dependent SREBP1c degradation would require 
for RNF20. These data strongly indicate that RNF20 is a negative regulator of 
SREBP1c and the lipogenic program upon PKA activation in hepatocytes. 
 
RNF20 represses hepatic lipid metabolism in vivo. 
To further examine whether RNF20 confers hepatic lipid metabolism via 
SREBP1c in vivo, adenovirus expressing RNF20 was intravenously injected into 
wild-type mice. In agreement with the above data, in vivo RNF20 overexpression 
decreased the level of hepatic SREBP1 protein (Figure 17A). Consistently, the 
hepatic triglyceride level was decreased by RNF20 overexpression (Figure 17B). 
To confirm the possibility that the decrease in hepatic lipid metabolism is mediated 
by RNF20-dependent SREBP1c suppression, I tested FASN promoter activity in 
vivo. As shown in Figure 17C, optical in vivo imaging analyses revealed that 
adenoviral RNF20 overexpression repressed FASN promoter activity compared 
with control mice. In addition, I found that the expression of lipogenic genes such 
as SREBP1c, FASN, SCD1, and ELOVL6 was significantly attenuated in the liver of 
RNF20-overexpressing mice (Figure 17D). However, hepatic RNF20 over-
expression did not significantly alter the mRNA level of other SREBPs such as 
SREBP1a and 2 (Figure 17D). Moreover, adenovirally ovevexpressed RNF20 in 
vivo did not change the mRNA levels of other lipogenic transcription factors, 





Figure 17. RNF20 overexpression inhibits the hepatic lipogenic program in 
vivo. (A) Ten-week-old male C57BL/6 mice were infected through the tail vein 
with adenovirus encoding GFP (Ad-Mock) as the control or mouse RNF20 (Ad-
RNF20) (adenoviral dose of 1×1010 viral particles per mouse). After 7 days of 
adenoviral injection, the mice were sacrificed in fed states. The expression levels of 
RNF20, nSREBP1 and FASN protein in the livers of mice infected with Ad-Mock 
or Ad-RNF20 were monitored by western blotting analyses. nSREBP1, nuclear 
SREBP1. (B) The hepatic triglyceride level was measured from 100 mg liver tissue 
as described in “Materials and Methods”. *P < 0.05 was considered significant (vs. 
the Ad-Mock control group). (C) Live imaging of in vivo FASN-luciferase (FASN-
luc) activity in response to RNF20 overexpression in C57BL/6 mice. In vivo 
luminescence was measured 7 days post-adenoviral infection as described in 
“Materials and Methods”. (D) In C57BL/6 mouse liver injected Ad-Mock or Ad-
RNF20, the effects of adenoviral RNF20 overexpression on lipogenic gene 
expression were determined by qRT-PCR analyses. The level of TBP mRNA was 
used for normalization. Each mRNA level is shown as a ratio relative to the Ad-
Mock control group. *P < 0.05 was considered significant (vs. the Ad-Mock 

































liver (Figure 17D). Thus, these in vivo data confirm the notion that RNF20 plays an 
important role in the regulation of hepatic lipogenesis via SREBP1c. 
 
RNF20 alleviates hepatic steatosis in db/db mice. 
Several obese rodent animals, including db/db mice, exhibit hepatic 
steatosis with enhanced SREBP1c and lipogenic activity (Li et al., 2005; 
Marchesini et al., 2001; Muoio and Newgard, 2006). To investigate whether 
RNF20 overexpression might alleviate fatty liver through the regulation of 
SREBP1c, RNF20 was overexpressed by adenovirus in the liver of db/db mice. In 
db/db mice, adenoviral overexpression of RNF20 did not cause major differences 
in body weight and fasting blood glucose (Figures 18A and 18B). Similar to lean 
mice, hepatic RNF20 overexpression decreased both precursor and nuclear forms 
of SREBP1 protein in db/db mice (Figure 19A). In accordance with reduced 
SREBP1 expression, hepatic steatosis was alleviated by RNF20 overexpression in 
db/db mice (Figures 19B and 19C). Furthermore, hepatic RNF20 overexpression in 
db/db mice significantly lowered FASN promoter activity (Figure 19D) and 
reduced the expression of lipogenic genes (Figure 20A). However, similar to lean 
mice, hepatic RNF20 overexpression in db/db mice did not alter the mRNA levels 
fatty acid oxidation pathway genes (Figure 20B), indicating that hepatic RNF20 
overexpression would alleviate hepatic steatosis by suppression of SREBP1c and 
lipogenic gene expression. Next, to investigate whether hepatic RNF20 might be 
involved in glucose homeostasis in diabetic db/db mice, oral glucose tolerance tests 
were examined. As shown in Figure 20C, RNF20 overexpression improved glucose 











Figure 18. In db/db mice, RNF20 overexpression did not cause differences in 
body weight and fasting blood glucose. Nine-week-old male db/db mice were 
infected through the tail vein with adenovirus encoding GFP or RNF20 (adenoviral 
dose of 2×1010 viral particles per mouse). After 7 days of adenoviral injection, the 
mice were sacrificed. (A) Body weight (grams) of Ad-Mock or Ad-RNF20 injected 
db/db mice. (B) Fasting glucose levels (mg/dL) of Ad-Mock or Ad-RNF20 injected 











































Figure 19. RNF20 overexpression alleviates hepatic steatosis in db/db mice.  
(A) Nine-week-old male db/db mice were infected through the tail vein with 
adenovirus encoding GFP or RNF20 (adenoviral dose of 2×1010 viral particles per 
mouse). After 7 days of adenoviral injection, the mice were sacrificed in fed states. 
The liver tissue was then subjected to SDS-PAGE followed by western blotting 
analyses with the indicated antibodies. n = 3 for each group. (B) The level of 
hepatic triglycerides was measured from 100 mg liver tissue in db/db mice infected 
with each adenovirus. n = 5 for each group. *P < 0.05 was considered significant 
(vs. the Ad-Mock control group). (C) Representative hematoxylin and eosin (H&E) 
and Oil Red O staining of liver sections of db/db mice infected with Ad-Mock or 
Ad-RNF20. Scale bar, 100 μm. (D) Live imaging of in vivo FASN-luciferase 











































Figure 20. RNF20 overexpression improved glucose intolerance in db/db mice. 
Nine-week-old male db/db mice were infected through the tail vein with 
adenovirus encoding GFP or RNF20 (adenoviral dose of 2×1010 viral particles per 
mouse). (A) The relative mRNA levels of various lipogenic genes in the livers of 
db/db mice infected with Ad-Mock or Ad-RNF20. Each mRNA level was 
determined by qRT-PCR analyses and normalized to the TBP mRNA level. Each 
relative mRNA level is presented as a ratio relative to the Ad-Mock-infected db/db 
control group. n = 3 for each group. *P < 0.05 and **P < 0.01 were considered 
significant (vs. the Ad-Mock control group). (B) The relative mRNA levels of 
PPARα and ChREBP pathway genes in the livers of db/db mice infected with Ad-
Mock or Ad-RNF20. Each mRNA level was determined by qRT-PCR analyses and 
normalized to the TBP mRNA level. n = 3 for each group. (C) db/db mice were 
infected with Ad-Mock or Ad-RNF20 and subjected to oral glucose tolerance test. 
n = 5 at each time point. *P < 0.05 and **P < 0.01 were considered significant  
(vs. the Ad-Mock control group). And this result was confirmed by area-under-the-


































RNF20 might also affect the regulation of whole body energy metabolisms such as 




Due to its key roles in lipid metabolism, several metabolic diseases are 
associated with SREBP1c dysregulation. Both animal models and human subjects 
with obesity and diabetes mellitus often suffer from hepatic steatosis and 
hyperlipidemia, accompanied by elevated SREBP1c (Li et al., 2005; Marchesini et 
al., 2001; Muoio and Newgard, 2006). Thus, elucidation of the molecular 
mechanisms of SREBP1c function and its lipogenic activity under physiological 
conditions is important. SREBP1c is controlled by several different mechanisms, 
including transcriptional regulation, proteolytic maturation and post-translational 
modifications (Giandomenico et al., 2003; Hirano et al., 2003; Hirano et al., 2001; 
Kim et al., 2004; Li et al., 2011; Ponugoti et al., 2010; Sundqvist et al., 2005). It 
has been reported that PKA, one of the fasting-induced kinases, phosphorylates 
SREBP1c and consequently suppresses lipogenic activity (Lu and Shyy, 2006). 
However, the factors that are involved in SREBP1c degradation under fasting 
conditions are poorly understood. Here, I demonstrated that SREBP1c protein is 
ubiquitinated and degraded by an E3 ubiquitin ligase concurrent with PKA 
activation during fasting (Figure 21). 
RNF20 was first identified as yeast Bre1 and possesses a RING finger 
domain that primarily functions as an E3 ligase for histone H2B 
monoubiquitination, which regulates transcription of certain genes (Hwang et al., 
2003; Kim et al., 2005; Wood et al., 2003). In addition, it has been reported that 
knockdown of RNF20 leads to abrogation of H2B monoubiquitination and elevated 
expression of several proto-oncogenes for tumorigenesis, indicating that RNF20 











Figure 21. Model illustrating the regulatory pathway for RNF20-mediated 
degradation of SREBP1c upon PKA activation. RNF20 physically interacts with 
SREBP1c, leading to degradation of SREBP1c via ubiquitination. RNF20 represses 
SREBP1c activity and turns off the expression of lipogenic program in hepatocytes. 
Furthermore, PKA activation enhances the expression of RNF20 and potentiates 
the ubiquitination of SREBP1c. Taken together, RNF20-induced SREBP1c 




































However, to date, there is no report that RNF20 could selectively regulate hepatic 
lipid metabolism. In this work, I have identified that RNF20 would act as a 
negative regulator of hepatic lipid metabolism in a SREBP1c-dependent pathway. 
Several lines of evidence from in vitro and in vivo data support the above idea. 
First, ectopic expression of RNF20 repressed SREBP1c and lipogenic gene 
expression in primary hepatocytes (Figure 12A) and the mouse liver (Figures 17D 
and 20A). Second, the level of nuclear SREBP1 protein and the expression of its 
target genes were increased by RNF20 knockdown in primary hepatocytes, 
accompanied by augmentation of intracellular lipid accumulation (Figures 13 and 
14). Moreover, the mRNA levels of other lipogenic factors, such as PPARγ, LXRα 
and ChREBP, and fatty acid oxidation pathway genes were not significantly altered 
by RNF20-overexpressing or suppressing conditions (Figures 13A, 14C, 17D, and 
20B), indicating that RNF20 would control hepatic lipid metabolism through 
SREBP1c modulation. 
In order to examine the effect of RNF20 on other SREBP isoforms such as 
SREBP1a and 2, I have tested the effect of RNF20 on degradation of SREBP1a 
and 2. As shown in Figure 22, RNF20 was also able to induce the degradation of 
nuclear SREBP1a and 2, implying that RNF20 may regulate the stability of all 
isoforms of SREBP proteins, at least, in vitro cell culture system. Although RNF20 
may influence hepatic lipid metabolism via SREBP1a, 1c and/or 2, several current 
in vitro and in vivo data supported the idea that hepatic lipid metabolism would be 
primarily regulated by SREBP1c rather than 1a or 2 (Figures 12A, 13A, 16A, and 
17D). Nevertheless, future studies are necessary to clarify whether RNF20 might 












Figure 22. RNF20 regulates the stability of all isoforms of SREBP proteins. 
HEK293T cells were co-transfected with Myc-SREBP1a, Myc-SREBP1c, Myc-
SREBP2 and/or Flag-RNF20 expression vectors. Total cell lysates were subjected 






































Next, to test the possibility that the expression of hepatic RNF20 might be 
altered in pathophysiological conditions, I have examined the mRNA level of 
hepatic RNF20 by comparison with db/+ vs. db/db and normal-chow diet vs. high-
fat diet fed mice. Although the levels of lipogenic genes such as SREBP1c, FASN, 
and SCD1 were increased in the liver of insulin-resistant mouse models, the level 
of hepatic RNF20 was not significantly altered (Figures 23A and 23B). Thus, it is 
likely that RNF20 might regulate lipogenic activity upon hormonal changes in 
normal conditions rather than pathophysiological conditions. However, since 
overexpression of hepatic RNF20 markedly improved glucose intolerance in 
diabetic db/db mice (Figure 20C), I cannot exclude the possibility that hepatic 
RNF20 might affect glucose metabolism in vivo. Further studies are required to 
understand the detail mechanisms for the role of RNF20 in whole body energy 
homeostasis. 
Recently, it has been demonstrated that SREBP1c is dynamically modified 
by various post-translational modifications. For example, SIRT1 promotes the 
deacetylation-mediated ubiquitination of SREBP1c and represses lipogenic activity 
during fasting (Ponugoti et al., 2010; Walker et al., 2010). Additionally, another 
study showed that fasting-induced cyclin-dependent kinase 8 (CDK8) 
phosphorylates and sequentially degrades SREBP1c (Zhao et al., 2012). Although 
it is unknown whether RNF20-mediated ubiquitination of SREBP1c might be 
required for prerequisite post-translational modifications under catabolic conditions, 
I cannot exclude the possibility that any modification of SREBP1c might change 









Figure 23. The expression of RNF20 is not altered in mouse liver under obese 
and diabetic conditions. (A) Ten-week-old male db/+ and db/db mice were 
sacrificed and isolated the liver tissues in fed states. The mRNA levels of RNF20, 
SREBP1c, FASN, and SCD1 were determined by qRT-PCR analyses. The level of 
cyclophilin mRNA was used for normalization. n = 3 for each group. *P < 0.05 and 
**P < 0.01 were considered significant. (B) Eight-week-old male C57BL/6 mice 
were fed normal chow diet (NCD) and then were administered a 60% high-fat diet 
(HFD) for ten weeks. Then, on the day of sacrifice, all of the HFD-fed mice were 
compared to age-matched NCD-fed mice. In the mouse liver, the mRNA levels of 
RNF20, SREBP1c, SCD1, and IL-6 were determined by qRT-PCR analyses. The 
level of cyclophilin mRNA was used for normalization. n = 2 for each group.    


































In addition to RNF20, FBXW7 is another E3 ubiquitin ligase for SREBP1 
(Sundqvist et al., 2005). FBXW7-dependent SREBP1 degradation requires for 
GSK-3β-mediated phosphorylation of SREBP1 (Kim et al., 2004; Sundqvist et al., 
2005). It is of interest to note that RNF20 would induce the ubiquitination and 
degradation of SREBP1c upon PKA activation. In contrast, the expression level of 
FBXW7 was not altered by nutritional states such as feeding and fasting    
(Figure 15A). Furthermore, PKA activation did not change the level of FBXW7. 
Given that PKA plays a crucial role in immediate catabolic responses, PKA 
activation with forskolin significantly decreased lipogenic gene expression with an 
increase in RNF20 in primary hepatocytes, whereas suppression of RNF20 
reversed the effect of forskolin on lipogenic gene expression (Figure 16A), 
indicating that RNF20 might mediate the PKA signaling cascade to downregulate 
hepatic lipid metabolism via SREBP1c degradation. Additionally, it has been 
reported that suppression of FBXW7 in vivo causes fatty liver through the 
induction of PPARγ rather than SREBP1c (Kumadaki et al., 2011). On the contrary, 
RNF20 overexpression did not affect the protein levels of PPARγ and LXRα 
(Figure 24), implying that RNF20 functions as a “turn-off” switch in hepatic 
lipogenesis through the regulation of SREBP1c, but not PPARγ, protein stability. 
Therefore, these data clearly support the hypothesis that RNF20 acts as a negative 
regulator of SREBP1c and hepatic lipogenesis under catabolic conditions. 
Here, I have elucidated a novel mechanism of ubiquitination and 
degradation of SREBP1c by RNF20 during nutritional deprivation (Figure 21). It is 
plausible to speculate that RNF20 is a suppressor of hepatic lipogenesis through the 












Figure 24. RNF20 overexpression did not affect the protein levels of PPARγ 
and LXRα. HEK293T cells were co-transfected with Myc-PPARγ, Myc-LXRα 
and/or Flag-RNF20 expression vectors. Total cell lysates were subjected to SDS-





































provide a clue to understand how SREBP1c is rapidly regulated by fasting signals 
to prevent excess lipid metabolism. Because there is a positive correlation between 
lipogenic activity and metabolic complications such as obesity, non-alcoholic fatty 
liver disease (NAFLD), and certain cancers, it is likely that treatments that activate 
RNF20 might be useful tools for ameliorating metabolic disorders associated with 













Ring finger protein 20 downregulation promotes 
tumorigenesis by sterol regulatory element-binding protein 
1c-mediated lipogenesis and cell cycle regulation in clear cell 










In cancer cells, elevated lipid metabolism plays an important role by 
providing building blocks for tumor growth. Particularly, clear cell renal cell 
carcinoma (ccRCC), the most common subtype of kidney cancers, is characterized 
by ectopic intracellular lipid accumulation. However, the relationship between lipid 
metabolism and tumorigenesis in ccRCC has not been thoroughly elucidated. Here 
I demonstrate that ring finger protein 20 (RNF20) acts as a tumor suppressor in 
ccRCC. In ccRCC tumor tissues, RNF20 is downregulated, accompanied with 
sterol regulatory element-binding protein 1c (SREBP1c) activation and poor 
prognosis. In ccRCC cells, RNF20 overexpression repressed lipogenesis and cell 
proliferation by inhibiting SREBP1c. Notably, SREBP1c regulates cell cycle 
progression by inducing pituitary tumor-transforming gene 1 (PTTG1) as a novel 
SREBP1c target gene. Moreover, suppression of SREBP1 by either knockdown or 
small-molecule inhibitor betulin attenuated cell proliferation with decreased 
expression of PTTG1 and several cell-cycle regulators in ccRCC cells. 
Furthermore, xenograft studies showed that ectopic RNF20 expression reduced 
tumor growth and lipid storage. Taken together, these data suggest that RNF20 
suppresses tumorigenesis in ccRCC by regulating SREBP1c-dependent lipogenesis 




Increased demands for building blocks and membrane biogenesis during 
excessive cell proliferation of cancer cells are satisfied by complex metabolic 
reprogramming (DeBerardinis et al., 2008; Schulze and Harris, 2012). Especially, 
most lipid metabolites are derived from de novo lipogenesis in cancer cells rather 
than from extracellular lipid uptake (Medes et al., 1953; Ookhtens et al., 1984). 
Moreover, it has been reported that lipogenesis and lipid accumulation are 
upregulated in various cancers (Kuhajda, 2000; Menendez and Lupu, 2007). 
Ectopic lipid accumulation is a hallmark of clear cell renal cell carcinoma (ccRCC), 
which is the most common subtype of kidney cancers (Rezende et al., 1999; Valera 
and Merino, 2011). To date, the primary etiology of ccRCC follows the loss or 
inactivation of von Hippel-Lindau (VHL) and a consequent activation of hypoxia-
inducible factor (HIF) (Kaelin, 2008; Shen and Kaelin, 2013). Recently, it has been 
reported that HIF2α-selective antagonist, PT2399, effectively suppresses 
tumorigenesis in ccRCC (Chen et al., 2016; Cho et al., 2016). Although lipid and 
glucose metabolic pathways are frequently dysregulated in ccRCC (Linehan and 
Ricketts, 2013; Qiu et al., 2015), the underlying tumorigenic mechanisms that lead 
to aberrant lipogenesis in ccRCC remain poorly understood. 
Ring finger protein 20 (RNF20) is an E3 ubiquitin ligase that plays various 
roles in transcription regulation, DNA damage responses, stem cell differentiation, 
and lipid metabolism (Lee et al., 2014b; Nakamura et al., 2011; Shema et al., 2008). 
RNF20 promotes the monoubiquitination of histone H2B, which regulates the 
transcription of a subset of genes and contributes to chromatin remodeling (Minsky 
et al., 2008; Shema et al., 2008). Moreover, it has been suggested that RNF20 acts 
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as a tumor suppressor in inflammation-associated cancer (Tarcic et al., 2016). 
I demonstrated that hepatic RNF20 is an E3 ubiquitin ligase for sterol 
regulatory element-binding protein 1c (SREBP1c), which is a key transcription 
factor in de novo lipogenesis (Brown and Goldstein, 1997; Tontonoz et al., 1993). 
RNF20 promotes polyubiquitination and degradation of SREBP1c upon PKA 
activation, thereby suppressing hepatic lipid metabolism (Lee et al., 2014b). In 
mammals, SREBP1a and SREBP1c are encoded by the SREBF1 gene, whereas 
SREBP2 is encoded by the SREBF2 gene (Brown and Goldstein, 1997; Horton et 
al., 2002). SREBP1 primarily activates genes that are involved in fatty acid 
synthesis, including fatty acid synthase (FASN), stearoyl-CoA desaturase 1 (SCD1), 
and long-chain fatty acid elongase (ELOVL6), whereas SREBP2 mainly promotes 
the expression of genes for cholesterol homeostasis, such as HMG-CoA reductase 
(HMGCR) (Brown and Goldstein, 1997; Horton et al., 2002). It has been reported 
that activated SREBP1c upregulates lipogenic genes and enhances lipogenesis in 
certain cancers (Griffiths et al., 2013; Guo et al., 2014). In addition, SREBP1c 
promotes lipid metabolism and tumor development, potentiating progression, 
migration, and leading to poor prognosis for several cancers (Guo et al., 2009; 
Huang et al., 2012). However, the molecular mechanisms by which SREBP1c 
promotes cancer cell proliferation are not clearly understood. 
In this study, I uncover that RNF20 suppressed ccRCC tumorigenesis by 
inhibiting SREBP1c, and RNF20 downregulation stimulated SREBP1c-mediated 
lipogenesis and cell proliferation. In accordance with these data, genetic and 
pharmacologic inhibition of SREBP1 decreased lipogenesis and cell growth in 
ccRCC cells. Notably, downregulation of RNF20 in ccRCC cells augmented cell 
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cycle progression by activating SREBP1c-mediated pituitary tumor-transforming 
gene 1 (PTTG1). Together, these findings suggest that RNF20 functions as a tumor 




Materials and Methods 
Cell culture and reagents 
ACHN, A498, HEK293, Caki-2, and human primary renal cortical 
epithelial (HRCE) cells were obtained from American Type Culture Collection 
(ATCC). ACHN and A498 cells were grown in in Eagle‟s minimum essential 
medium (MEM; HyClone, Logan, UT; #SH30024.01) supplemented with 10% 
fetal bovine serum (FBS; HyClone; #SH30919.03) and penicillin (100 U/ml)-
streptomycin (100 μg/ml). HEK293 and Caki-2 cells were grown in Dulbecco‟s 
modified Eagle medium (DMEM; HyClone; #SH30243.01) supplemented with  
10% FBS and penicillin-streptomycin. HRCE cells were cultured in renal epithelial 
cell basal medium (ATCC; #PCS-400-030) with the following supplements: 0.5% 
FBS, 10 nM triiodothyronine, 10 ng/ml epidermal growth factor, 100 ng/ml 
hydrocortisone, 5 μg/ml insulin, 1 μM epinephrine, 5 μg/ml transferrin, 2.4 mM  
L-Alanyl-L-Glutamine, and penicillin-streptomycin. All cells were cultured at 
37°C in a 5% CO2 incubator. Betulin and BODIPY 493/503 were purchased from 
Sigma-Aldrich (St. Louis, MO; #B8936 and #D3922, respectively). C75 and TOFA 
were obtained from Abcam (Cambridge, MA; #ab141397 and #ab141578, 
respectively). Propodium iodide was provided by BD Biosciences (San Jose, CA; 
#51-66211E). 
 
Human ccRCC samples 
Fresh frozen human ccRCC and matched normal kidney tissue samples 
were obtained from the Seoul National University Hospital (SNUH). The 
Institutional Review Board at SNUH approved this study (approval number:    
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H-1501-011-636). Informed consent documents from patients were not required 
due to the retrospective nature of the study. 
 
TCGA RNA-Seq analysis 
RNA sequencing data, VHL mutation status, and clinicopathological data 
for 533 ccRCC and 72 normal kidney samples were downloaded from TCGA 
ccRCC project (http://cancergenome.nih.gov) in September 2015. Box and whisker 
plots are presented with 1–99th percentiles (bars), 25–75th percentiles (box), and 
median values (line in box). 
 
Survival analysis 
Available patient survival data were obtained from TCGA ccRCC project. 
Patients were ranked on tumor expressions of the genes shown in TCGA RNA-Seq 
data. The top half of ranked patients was defined as the „high‟ group, and the lower 
half were defined as the „low‟ group. Overall survival curves were estimated using 
Kaplan–Meier survival analyses, and survival outcomes between the two groups 
were compared using the Log-rank test. 
 
Tissue arrays and immunohistochemistry 
Immunohistochemistry was performed on tissue microarrays of ccRCC 
and normal kidney tissue sections (SuperBioChips Laboratories, South Korea; 
#CL2) according to the supplier‟s protocol (Ventana Medical Systems; #760-700). 
Briefly, the streptavidin–biotin complex method was used to detect RNF20 and 
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SREBP1 in immunohistochemistry analyses with corresponding primary antibodies 
from Abcam (#ab32629; 1:30) and BD Biosciences (#557036; 1:25), respectively. 
 
Preparation of recombinant adenovirus 
Adenovirus plasmids were constructed as previously described (Lee et al., 
2014b). Briefly, nuclear rat SREBP1c encoding amino acids 1–403, and full-length 
mouse RNF20 cDNAs were incorporated into the AdTrack-CMV shuttle vector 
and recombinant vectors were generated using Ad-Easy adenoviral vector systems. 
An adenovirus encoding GFP only was used as a negative control in all 
experiments. Adenoviruses were amplified in HEK293A cells and were purified 
using CsCl gradient centrifugation as described previously (Becker et al., 1994). 
 
Lentivirus production and viral transduction 
Full-length RNF20 or nuclear SREBP1c cDNAs with Flag-tags were 
incorporated into the lentiviral vector pLVX-EF1α-AcGFP1-N1 (Clontech, 
Mountain View, CA; #631983). Lentiviruses were then transfected into HEK293T 
cells with the indicated expression vectors, pAX2 (Addgene, Cambridge, MA; 
#35002) and pMD2.G (Addgene; #12259) using Lipofectamine 2000 Reagent 
(Invitrogen, Grand Island, NY; #11668-027). At 48 hours after transfection, viruses 
were harvested and filtered through 0.45-μm filters. Subsequently, ACHN cells 
were incubated with medium containing virus and 8 μg/ml polybrene (Sigma-
Aldrich; #107689) for 18 hours. Infected cells were then allowed to recover for  
48 hours before selection of puromycin resistant colonies for experiments. 
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Western blot analysis 
Cells and tissues were lysed on ice in modified radioimmunoprecipitation 
assay (RIPA) buffer containing 150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 1%  
NP-40, 0.25% Na-deoxycholate, 1 mM EDTA, 1 mM PMSF, and protease 
inhibitor cocktail (GeneDEPOT, Katy, TX; #P3100). Equal amounts of protein 
from each sample were separated on SDS-PAGE gels and were then transferred to 
polyvinylidene difluoride membranes (Merck Millipore, Germany; #IPVH00010). 
After transfer, membranes were blocked with 5% non-fat milk or 3% bovine serum 
albumin in TBS containing 0.1% Tween-20 (TBST) and were probed with primary 
antibodies against RNF20 (Abcam; #ab32629; 1:1,000), SREBP1 (BD Biosciences; 
#557036; 1:1,000), FASN (Cell Signaling, Danvers, MA; #3180; 1:1,000), SCD1 
(Santa Cruz Biotechnology, Dallas, TX; #SC-58420; 1:500), PTTG1 (Thermo 
Fisher Scientific, Waltham, MA; #MS-1511-P0; 1:1,000), Cyclin B1 (Santa Cruz 
Biotechnology; #SC-752; 1:500), Cyclin E (Santa Cruz Biotechnology; #SC-198; 
1:500), Myc-tag (Cell Signaling; #2276; 1:1,000), Flag-tag (Sigma-Aldrich; 
#F1804; 1:1,000), or β-actin (Sigma-Aldrich; #A5316; 1:2,000). Subsequently, 
membranes were incubated with horseradish peroxidase-conjugated secondary 
anti-rabbit IgG or anti-mouse IgG antibodies (Sigma-Aldrich; #A0545 and #A9044, 
respectively), and protein bands were visualized using enhanced 
chemiluminescence with a LuminoImager (LAS-3000). 
 
RNA isolation and quantitative RT-PCR 
Total RNA was isolated using TRIzol Reagent (Thermo Fisher Scientific; 
#15596026). Subsequently, equal amounts of RNA were subjected to cDNA 
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synthesis using RevertAid reverse transcriptase (Thermo Fisher Scientific; 
#EP0441), and relative mRNA expression was evaluated using a CFX Real-Time 
System (Bio-Rad Laboratories, Hercules, CA) and was normalized to GAPDH or 
cyclophilin mRNA expression. The primer sequences used for quantitative real-
time PCR (qRT-PCR) analyses are listed in Table 3. 
 
siRNA transfection 
Small-interference RNA (siRNA) duplexes for RNF20, SREBP1, PTTG1, 
and FASN were synthesized by Bioneer (South Korea). The sequence information 
for siRNAs is provided in Table 4. ACHN cells were transfected using 
Lipofectamine RNAiMAX Reagent (Invitrogen; #13778-150) according to the 
manufacturer‟s protocol. 
 
Cell proliferation assays with CCK-8 reagent 
Cell proliferation rates were determined using a Cell Counting Kit-8 
(CCK-8) reagent as described previously (Kim et al., 2010). Briefly, cell growth 
curves were generated using the sensitive colorimetric assay for viable cells 
according to the manufacturer‟s protocol (Dojindo Molecular Technologies, 
Rockville, MD; #CK04-11). 
 
Colony formation assays 
ACHN cells with lentiviral RNF20 and/or SREBP1c overexpression were 
seeded on 6-well plates (5,000 cells/well). Cells were cultured at 37°C in 5% CO2 
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Table 3. Primers sequences for qRT-PCR 
 
Species Gene Sequence (5’ to 3’) Direction 
Human 








































































Table 4. Sequences of siRNA oligos 
Species Gene Sequence (5’ to 3’) Direction 
Human 
























for 7 days, and colonies were then fixed with formaldehyde and were stained with 
crystal violet. 
 
Cell cycle analysis 
Trypsinized cells were washed with phosphate-buffered saline (PBS) and 
were then fixed in 70% ethanol at 4°C for 30 minutes. Fixed cells were washed 
with PBS twice and incubated with propodium iodide (PI) solution containing   
0.1% Nonidet P-40, 100 μg/ml RNase, and 2.5 μg/ml PI for 30 minutes. Stained 
cells were then analyzed by flow cytometry using a FACS Canto II instrument (BD 
Biosciences), and numbers of cells in each stage were calculated using the ModFit 
LTTM cell cycle analysis program (Verity Software House) according to the 
manufacturer‟s instructions. 
 
Intracellular triglyceride measurements 
Intracellular triglycerides were determined in cell lysates using a 
colorimetric assay, and were expressed as mg of lipid per mg of cellular protein as 
described previously (Lee et al., 2014b). Briefly, total cell contents were extracted 
using 5% Triton X-100 and were incubated in a water bath at 80°C and 
subsequently cooled to room temperature twice. After centrifugation at 12,000 rpm 
for 5 minutes at room temperature, supernatants were collected and intracellular 
triglycerides were assayed using Infinity Triglycerides Reagent (Thermo Fisher 
Scientific; #TR22321). Values were normalized to total protein contents, which 
were estimated using a BCA Protein Assay Kit that is compatible with reducing 
agents (Thermo Fisher Scientific; #23250). 
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BODIPY staining 
ACHN cells were treated with or without betulin (10 μM) for 24 hours, 
were rinsed twice with PBS, and were then fixed in 4% paraformaldehyde for   
10 minutes. Subsequently, fixed cells were washed twice with PBS containing 
Tween-20, and were stained with fluorescein isothiocyanate (FITC)-conjugated 
BODIPY 493/503 (Thermo Fisher Scientific; #D3922) for 1 hour in the dark at 
room temperature. Samples were then stained with a Vectashield solution (Vector 
Laboratories, Burlingame, CA; #H-1200) containing 4‟,6-diamidino-2-
phenylindole (DAPI) and were observed using a Zeiss LSM 700 confocal 
microscope (Carl Zeiss, Germany). 
 
PTTG1 reporter and luciferase assays 
The PTTG1 luciferase reporter containing −908 to +25 nucleotides from 
the transcription start site of the human PTTG1 promoter was cloned into a pGL3-
basic vector (Promega, Madison, WI; #E1751). HEK293 cells were transiently 
transfected with various DNA plasmids using the calcium-phosphate method as 
described previously (Jang et al., 2016). After incubation for 36 hours, transfected 
cells were harvested and extracted using lysis buffer containing 25 mM Tris-
phosphate (pH 7.8), 10% glycerol, 2 mM EDTA, 2 mM DTT, and 1% Triton X-
100, and luciferase and β-galactosidase activities were measured according to the 
manufacturer‟s protocol (Promega; #E1500). Relative luciferase activity was 





Subcutaneous xenograft experiments were approved by the Institutional 
Animal Care and Use Committee (IACUC) of SNUH (IACUC number: 13-0080). 
Five female BALB/c athymic nude mice (Central Lab Animal, South Korea) were 
subcutaneously injected in both flanks with 1 × 107 vector control ACHN cells or 
ACHN cells stably expressing RNF20. Before injections, cells were resuspended in 
200 μl of PBS and were mixed with equal volumes of matrigel (Corning, NY; 
#354234). Following establishment of palpable tumors, tumor sizes were measured 
once a week using calipers, and tumor volumes were calculated according to the 
following formula: volume (mm3) = (length × width2) × π/6. After transplantation 
for 5 weeks, mice were killed by CO2 inhalation, and xenograft tumors were 
dissected and weighed. 
Xenograft tissue samples were fixed in 4% paraformaldehyde, equilibrated 
in 30% sucrose, and then embedded in OCT (Scigen Scientific, Gardena, CA; 
#4583). Sections (10 μm) were then cut stained with Hematoxylin and eosin (H&E) 
and Oil Red O as previously described (Ham et al., 2016). Immunohistochemistry 
analyses of xenograft tumor sections were performed according to the supplier‟s 
protocol (SuperBioChips Laboratories). Briefly, Ki67 and TUNEL proteins were 
detected using the streptavidin–biotin complex method with primary antibodies 
against Ki67 (Abcam; #ab66155) and TUNEL (R&D Systems; #4810-30-K). 
Images were obtained using an EVOS ORIGINAL microscope (Thermo Fisher 





All results reported in the main and Supplementary figures are presented 
as mean ± SD or mean ± SEM (for Figures 46B and 46C). Multiple comparisons 
were performed using one-way analysis of variance (ANOVA), and two-way 
ANOVA when two conditions were involved. Statistical significance was assessed 
by the two-tailed Student‟s t-test. Statistical analyses were performed using Prism 




RNF20 is downregulated in ccRCC. 
Ectopic lipid accumulation is profoundly upregulated in ccRCC (Rezende 
et al., 1999; Valera and Merino, 2011). Because RNF20 reportedly acts as a 
negative regulator of de novo lipogenesis by inhibiting SREBP1c (Lee et al., 
2014b), I investigated whether RNF20 might be dysregulated in ccRCC tumors. As 
shown in Figure 25A, RNF20 mRNA expression was greatly downregulated in 
ccRCC tumors compared with that in patient-matched normal kidney tissues. 
Similarly, RNA-Seq data from the Cancer Genome Atlas (TCGA) show significant 
reductions in RNF20 mRNA expression in ccRCC tumors (Figure 25B) and 
indicate that low RNF20 expression is closely correlated with advanced tumor 
stages (Figure 25C). Furthermore, immunohistochemistry (IHC) analyses showed 
that RNF20 protein expression was lower in ccRCC tumors than adjacent normal 
kidney tissues (Figure 25D). In agreement, RNF20 staining data from patient-
matched normal kidney and tumor tissues revealed decreased RNF20 expression in 
ccRCC (Figure 25E). RNF20 expression was also decreased in ccRCC cell lines 
A498, Caki-2, and ACHN compared with that in human primary renal cortical 
epithelial (HRCE) and HEK293 normal kidney cells (Figure 25F). In a previous 
study, the promoter region of RNF20 was selectively hypermethylated in breast 
cancer tissues (Shema et al., 2008). Thus, to determine whether hypermethylation 
of RNF20 promoter might downregulate RNF20 expression in ccRCC, I inhibited 
DNA methyltransferases (DNMTs) using the inhibitor RG108 and determined the 
expression levels of RNF20 mRNA in ccRCC cells. Treatment with RG108 








Figure 25. RNF20 is downregulated in ccRCC. (A) qRT-PCR analyses of RNF20 
in patient-matched ccRCC tumor (n = 9) and normal kidney (n = 9) samples. RNF20 
mRNA expression was normalized to those in matched normal kidney samples.  
(B) Normalized RNA-Seq reads of RNF20 in ccRCC tumors (n = 533) and normal 
kidney (n = 72) samples. RNA-Seq data were obtained from TCGA ccRCC project. 
(C) RNF20 expression in ccRCC tumors was analyzed according to tumor stages. 
RNA-Seq data were obtained from TCGA. ##P < 0.01 versus normal kidney;   
###P < 0.001 versus normal kidney. (D) Immunohistochemistry (IHC) staining of a 
representative ccRCC tissue microarray with an RNF20 antibody. (E) IHC staining 
of matched ccRCC tumor and adjacent normal kidney tissues. Representative tissue 
sections with RNF20 staining. Scale bar, 100 μm. (F) RNF20 protein expression in 
normal kidney cell lines such as human primary renal cortical epithelial (HRCE) 
and HEK293, and ccRCC cell lines including ACHN, A498, and Caki-2 were 
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Figure 26. The DNA methyltransferase inhibitor RG108 leads to an increase in 
RNF20 expression in ccRCC cells. (A) ACHN ccRCC cells were treated with or 
without RG108 (+; 250 μM or ++; 1 mM). After incubation for 48 hours, relative 
mRNA levels were determined using qRT-PCR. RNF20 mRNA level was 
normalized to that of cyclophilin gene and is presented relative to that in the 
vehicle group. Data are presented as mean ± SD of three individual samples.    
*P < 0.05. (B) HEK293 cells were incubated with or without RG108 (+; 250 μM or 
++; 1 mM) for 48 hours, and relative mRNA levels were determined using qRT-
PCR. RNF20 mRNA level was normalized to that of cyclophilin gene and is 
presented relative to that in the vehicle group. Data are presented as means ± SD of 
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cells (Figures 26A and 26B). Subsequently, I explored the relationship between 
RNF20 expression and clinical outcomes, and showed that low expression of 
RNF20 is significantly correlated with poor survival (Figure 27A). This close 
correlation between RNF20 and poor prognosis was observed in VHL wild-type 
and in VHL mutant ccRCC patients (Figures 27B and 27C). Thus, to evaluate 
tumorigenic consequences of low RNF20 expression, I determined whether RNF20 
might affect cell proliferation in VHL wild-type ACHN and VHL-depleted A498 
ccRCC cells. In these experiments, overexpression of RNF20 suppressed cell 
proliferation in ACHN and A498 ccRCC cells (Figures 28A and 28B). Conversely, 
siRNA-mediated suppression of RNF20 increased cell growth in ccRCC cell lines, 
including ACHN and A498 cells (Figures 28C and 28D). In contrast, neither 
overexpression nor siRNA-mediated knockdown of RNF20 affected the growth of 
HRCE and HEK293 normal kidney cells, which have high levels of RNF20  
(Figure 29, A-D). These data indicate that RNF20 would act as a tumor suppressor 
in ccRCC cells independently of VHL mutation status. 
 
SREBP1 and lipogenic genes are upregulated in ccRCC and are negatively 
correlated with RNF20 expression. 
Several types of tumors such as glioblastoma, hepatic, prostate, and 
pancreatic cancers express high levels of SREBP1 and lipogenic genes, which are 
also positively correlated with malignant progression and worse outcomes 
(Griffiths et al., 2013; Guo et al., 2014; Guo et al., 2009; Huang et al., 2012). 












Figure 27. Low expression of RNF20 is correlated with poor survival in 
ccRCC patients regardless of VHL mutation status. (A) Kaplan–Meier survival 
curves of 532 ccRCC patients enrolled in TCGA database. Patients were divided 
into two groups according to median RNF20 mRNA levels, and differences were 
identified using the Log-rank test. (B and C) Survival analyses were stratified 












































Figure 28. RNF20 exhibits tumor-suppressive roles in ccRCC. (A) ACHN and 
A498 ccRCC cells were infected with adenovirus containing GFP alone (Mock) or 
Myc-RNF20. After infection for 24 hours, total cell lysates were subjected to SDS-
PAGE and western blotting analyses with indicated antibodies. (B) ACHN and 
A498 human ccRCC cell lines were infected with adenovirus containing GFP alone 
(Mock) or RNF20, and proliferation rates were monitored using CCK-8 assays. 
Data are presented as mean ± SD of five individual samples. (C) ACHN and A498 
ccRCC cells were transfected with nonspecific control siRNA (siControl) or 
RNF20-specific siRNA (siRNF20), and RNF20 expression was determined in 
western blotting analyses. (D) ACHN and A498 ccRCC cells were transfected with 
siControl or siRNF20, and relative growth rates were measured using CCK-8 










































Figure 29. RNF20 does not affect proliferation of normal kidney cells with 
high basal RNF20 expression. (A) Human primary renal cortical epithelial 
(HRCE) and HEK293 cells were infected with adenovirus containing Mock or 
Myc-RNF20, and cell lysates were examined using western blotting analyses.   
(B) HRCE and HEK293 cells were infected with adenoviral RNF20, and cell 
proliferation rates were monitored using CCK-8 assays. Data are presented as 
means ± SD of five individual samples. (C) HRCE and HEK293 cells were 
transfected with siControl or siRNF20, and cell lysates were then analyzed using 
western blotting. (D) HRCE and HEK293 cells were transfected with siRNF20, 
and relative cell growth rates were measured using CCK-8 assays. CCK-8, Cell 



































associated with ectopic lipid storage in ccRCC. Thus, I analyzed the expression 
patterns of lipogenic genes in normal kidney and ccRCC tumor tissues. As shown 
in Figure 30A, SREBP1c mRNA was significantly upregulated in ccRCC tumors 
compared with that in patient-matched normal samples. In addition, TCGA RNA-
Seq data revealed that SREBP1 was upregulated in ccRCC tumors (Figure 30B) 
and was positively associated with advanced tumor stages (Figure 30C). In 
accordance with these data, mRNA levels of the SREBP1 target genes for FASN 
and SCD1 were elevated in ccRCC tumors (Figure 30, D-I). Moreover, protein 
expression of SREBP1 and the lipogenic enzymes FASN and SCD1 were 
concurrently increased in ccRCC tumors compared with those in patient-matched 
normal kidney tissues, whereas RNF20 protein was downregulated (Figure 31A). 
Next, I examined the relationship between RNF20 and SREBP1 expression using 
IHC staining in matched normal kidney and tumor tissue sections from the same 
ccRCC patient. RNF20 signal intensity was reduced in ccRCC tumor tissues, 
whereas SREBP1 signals were increased (Figure 31B). Subsequent TCGA analyses 
revealed an inverse correlation between RNF20 and SREBP1 expression in ccRCC 
tumor tissues (Figure 31C). Accordingly, mRNA expression of RNF20 was 
inversely correlated with that of SREBP1c target genes ELOVL6 and FASN 
(Figures 31D and 31E), and FASN mRNA expression was positively correlated 
with poor survival (Figure 31F). In contrast, qRT-PCR and TCGA RNA-Seq 
analyses showed that the mRNA levels of SREBP2 and its target gene HMGCR, 
the rate-limiting enzyme of cholesterol synthesis, were decreased in ccRCC tumors 
(Figure 32, A-D). Together, these results imply that elevated SREBP1 levels might 







Figure 30. SREBP1 and lipogenic genes are upregulated in ccRCC. (A) qRT-
PCR analysis of SREBP1c in patient-matched ccRCC tumor and normal kidney 
samples. SREBP1c mRNA expression was normalized to those of matched normal 
kidney samples. (B) Normalized RNA-Seq reads of SREBP1 in ccRCC tumors and 
normal kidney samples. RNA-Seq data were obtained from TCGA ccRCC project. 
(C) ccRCC tumors were analyzed for SREBP1 expression according to tumor 
stages. (D) qRT-PCR analysis of FASN in patient-matched ccRCC tumor and 
normal kidney samples. FASN mRNA expression was normalized to those in 
matched normal kidney samples. (E) Normalized RNA-seq reads of FASN in 
ccRCC tumors and normal kidney samples. (F) FASN expression was analyzed in 
ccRCC tumors according to tumor stages. (G) qRT-PCR analysis of SCD1 mRNA 
level in matched ccRCC tumor and normal kidney samples. SCD1 mRNA 
expression was normalized to those in matched normal kidney samples.        
(H) Normalized RNA-seq reads of SCD1 in ccRCC tumors and normal kidney 
samples. (I) SCD1 expression was determined in ccRCC tumors of various tumor 
stages. #P < 0.05 versus normal kidney; ###P < 0.001 versus normal kidney;   
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Figure 31. Lipogenic enzymes are upregulated in ccRCC and are inversely 
correlated with RNF20 expression. (A) Protein levels in matched ccRCC tumor 
and normal kidney samples were determined using western blotting analyses. Total 
cell lysates were subjected to SDS-PAGE followed by western blotting analyses 
with indicated antibodies. (B) IHC staining of matched ccRCC tumors and adjacent 
normal kidney tissues. Representative tissue sections are shown with RNF20 and 
SREBP1 staining. Scale bar, 100 μm. (C) Correlations between RNF20 and 
SREBP1 mRNA levels in ccRCC tumor samples were identified in data from 
TCGA datasets using Pearson correlation tests. Numbers of cases (n), Pearson 
correlation coefficient (r), and P values (P) are indicated. (D) Correlations of 
RNF20 and ELOVL6 mRNA expression in ccRCC samples were identified in 
TCGA ccRCC datasets using Pearson correlation tests. (E) Correlation of RNF20 
and FASN mRNA expression in ccRCC samples were determined in TCGA ccRCC 
datasets and were identified using Pearson correlation tests. (F) Kaplan–Meier 
survival analysis for ccRCC patients from low or high FASN expression groups.  
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Figure 32. SREBP2 and its target gene HMGCR are decreased in ccRCC 
tumors. (A) qRT-PCR analysis of SREBP2 in matched ccRCC tumor and normal 
kidney samples. SREBP2 mRNA expression was normalized to that in matched 
normal kidney samples. (B) Normalized RNA-seq reads of SREBP2 in ccRCC 
tumors and normal kidney samples using TCGA ccRCC datasets. (C) qRT-PCR 
analysis of HMGCR in matched ccRCC tumor and normal kidney samples. 
HMGCR mRNA expression values were normalized to those in matched normal 
kidney samples. (D) Normalized RNA-seq reads of HMGCR in ccRCC tumors and 
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RNF20 alleviates lipogenesis and cell proliferation by repressing SREBP1c in 
ccRCC cells. 
I investigated the effects of RNF20 and/or SREBP1c overexpression in 
ccRCC cells. In VHL wild-type ACHN ccRCC cells, ectopic expression of RNF20 
clearly suppressed both endogenous and ectopic nuclear SREBP1 proteins  
(Figure 33A). However, suppression of RNF20 using siRNA led to increased 
SREBP1c protein and mRNA expression (Figures 33B and 33C). In agreement, 
SREBP1c overexpression augmented mRNA levels of lipogenic genes including 
FASN, ACC1, SCD1, and ELOVL6 in ACHN cells (Figure 34A), as shown in 
previous reports (Brown and Goldstein, 1997; Horton et al., 2002). In contrast, 
RNF20 potently inhibited mRNA expression of lipogenic genes in both control and 
SREBP1c-overexpressing ACHN cells (Figure 34A). However, suppression of 
RNF20 increased mRNA expression of lipogenic genes, and knockdown of both 
RNF20 and SREBP1 abolished the effects of RNF20 siRNA on the expression of 
lipogenic genes (Figure 34C). Accordingly, intracellular triglyceride accumulations 
were greater in SREBP1c-overexpressing ACHN cells than in control ACHN cells, 
whereas intracellular triglyceride levels were decreased by RNF20 overexpression 
(Figure 34B). Conversely, suppression of RNF20 increased intracellular 
triglyceride levels (Figure 34D). It has been reported that loss of SREBP1 
markedly decreases glioma cell proliferation (Guo et al., 2009; Williams et al., 
2013). In accordance with these, SREBP1c overexpression promoted mRNA 
expression of cell-cycle regulators including PCNA, cyclin A, D1, and E in ccRCC 
cells (Figure 35A), and concomitant RNF20 overexpression reduced the effects of 









Figure 33. RNF20 suppresses the expression of SREBP1c in ccRCC cells.    
(A) ACHN ccRCC cells were infected with adenovirus containing Myc-RNF20 
and/or Flag-SREBP1c. After infection, total cell lysates were subjected to SDS-
PAGE followed by western blotting analyses with the indicated antibodies. 
nSREBP1, nuclear SREBP1. (B) ACHN ccRCC cells were transfected with 
siRNF20 and/or siSREBP1. After incubation for 48 hours, total cell lysates were 
subjected to SDS-PAGE and western blotting analyses with indicated antibodies. 
(C) RNF20 and/or SREBP1 were knocked down in ACHN ccRCC cells using 
siRNAs, and relative mRNA levels were determined using qRT-PCR. Subsequently, 
mRNA expression was normalized to that of the GAPDH gene, and is presented 









































Figure 34. In ccRCC cells, RNF20 represses lipogenic activity by inhibiting 
SREBP1c. (A) ACHN ccRCC cells were transduced with lentivirus for stable 
overexpression of RNF20 and/or SREBP1c. Relative mRNA levels were 
determined using qRT-PCR. The level of each mRNA was normalized to the 
mRNA level of the GAPDH gene. Each mRNA level is shown as a ratio relative to 
the Mock control group. (B) Intracellular triglyceride contents were measured in 
lentiviral RNF20 and/or SREBP1c overexpressing ACHN cells. (C) RNF20 and/or 
SREBP1 were knocked down in ACHN ccRCC cells using siRNAs, and relative 
mRNA levels were determined using qRT-PCR. Subsequently, mRNA expression 
was normalized to that of the GAPDH gene, and is presented relative to those in 
the siControl group. (D) ACHN ccRCC cells were transfected with siRNF20 and/or 




































cycle gene expression in ccRCC cells (Figure 35D). In contrast, RNF20 
overexpression reduced colony formation whereas ectopic SREBP1c expression 
elevated colony formation in ACHN cells (Figure 35C). In addition, SREBP1c 
overexpression potentiated ccRCC cell proliferation (Figure 35B), and knockdown 
of SREBP1 reduced cell proliferation in both control and RNF20-suppressing cells 
(Figure 35E). These data propose that RNF20 would inhibit ccRCC cell 
proliferation by suppressing SREBP1c-induced lipogenesis and cell cycle 
progression. 
 
PTTG1 is a novel target gene of SREBP1c in ccRCC cells. 
As a transcriptional activator, it has been reported that SREBP1c 
stimulates fatty acid metabolism and cell cycle progression (Bengoechea-Alonso 
and Ericsson, 2006; Jeon et al., 2013; Williams et al., 2013). To identify further 
factor(s) that are involved in SREBP1c-induced cell cycle progression in ccRCC, I 
attempted to identify SREBP1c target genes that are involved in cell cycle 
regulation using RNA-Seq analyses in liver tissues of wild-type and SREBP1c 
deficient mice, and identified PTTG1 as a novel target gene of SREBP1c   
(Figure 36A). As shown in Figure 36B, PTTG1 expression was remarkably 
reduced in kidney, liver, and adipose tissues of SREBP1c deficient mice compared 
with that in wild-type mice. Subsequently, I investigated PTTG1 expression in 
SREBP1c-overexpressing ACHN cells and found that ectopic SREBP1c expression 
increased PTTG1 mRNA expression, whereas RNF20 co-expression attenuated this 
effect (Figure 37A). However, under conditions of SREBP1 knockdown, RNF20 





Figure 35. RNF20 inhibits ccRCC cell proliferation by cell cycle regulation.  
(A) ACHN ccRCC cells were transduced with lentivirus for stable overexpression 
of RNF20 and/or SREBP1c. Relative mRNA levels were determined using qRT-
PCR. The level of each mRNA was normalized to the mRNA level of the GAPDH 
gene. Each mRNA level is shown as a ratio relative to the Mock control group.  
(B) ACHN ccRCC cells were transduced with RNF20 and/or SREBP1c lentivirus, 
and the cell proliferation rates were monitored by CCK-8 assay. (C) ACHN ccRCC 
cells were transduced with RNF20 and/or SREBP1c lentivirus, and their ability to 
form colonies was determined by crystal violet staining. (D) RNF20 and/or 
SREBP1 were knocked down in ACHN ccRCC cells using siRNAs, and relative 
mRNA levels were determined using qRT-PCR. Subsequently, mRNA expression 
was normalized to that of the GAPDH gene and is presented relative to those in the 
siControl group. (E) ACHN ccRCC cells were transfected with siRNF20 and/or 
siSREBP1, and relative cell growth rates were determined using CCK-8 assay. All 
experiments were repeated independently at least three times and representative 
results are shown. CCK-8, Cell Counting Kit-8; #P < 0.05 versus Control;      
##P < 0.01 versus Control; ###P < 0.001 versus Control; *P < 0.05; **P < 0.01; 








































Figure 36. PTTG1 is a novel target gene of SREBP1c using RNA-Seq analyses 
in SREBP1c deficient mice. (A) RNA-Seq analysis for transcriptome profiling of 
liver tissues from wild-type and SREBP1c deficient mice are presented as a scatter 
plot. (B) Kidney, liver, and adipose tissues were isolated from wild-type and 
SREBP1c deficient mice. Total RNA was extracted and relative mRNA levels were 
determined using qRT-PCR. Subsequently, mRNA expression values were 
normalized to that of the TATA-binding protein (TBP). EAT, epididymal adipose 
tissue; IAT, inguinal adipose tissue; BAT, brown adipose tissue; **P < 0.01;   




































Accordingly, SREBP1c promoted PTTG1 protein expression in ccRCC cells 
(Figure 37C, lane 3). However, siRNA-mediated suppression of PTTG1 did not 
affect SREBP1c or FASN protein expression (Figure 37C, lane 4). To validate 
whether SREBP1c would regulate the transcription of PTTG1 directly, I analyzed 
putative sterol regulatory elements (SREs) and E-Box motifs, which are binding 
sites for SREBP1c (Kim et al., 1995; Shimano, 2001) in proximal promoter regions 
of PTTG1 genes in human, monkey, dog, mouse, and rat (Figure 38A). In 
luciferase reporter assays with the human PTTG1 promoter, SREBP1c expression 
induced luciferase activity and co-expression of RNF20 suppressed SREBP1c-
mediated PTTG1 promoter activation (Figure 38B). In ccRCC tumors, PTTG1 
mRNA levels were significantly upregulated compared to those in patient-matched 
normal kidney tissues (Figure 39A). TCGA analyses also showed that PTTG1 
mRNA levels were greatly enhanced in ccRCC tumor tissues (Figure 39B), and the 
expression of PTTG1 mRNA was positively associated with advanced tumor stages 
(Figure 39C). In addition, PTTG1 expression was inversely correlated with RNF20 
expression in ccRCC tumor tissues (Figure 39D). Moreover, high expression of 
PTTG1 was associated with a poor survival of ccRCC patients (Figure 39E). Taken 
together, these data suggest that activated SREBP1c would induce high expression 
of the novel target gene PTTG1 in ccRCC. 
 
The SREBP inhibitor betulin inhibits cell proliferation of ccRCC cells. 
Betulin is a pharmacological inhibitor that prevents proteolytic processing 
of SREBP proteins to achieve lipid-lowering effects (Soyal et al., 2015; Tang et al., 







Figure 37. PTTG1 is induced by SREBP1c in ccRCC cells. (A) ACHN ccRCC 
cells were transduced with RNF20 and/or SREBP1c lentivirus, and relative mRNA 
levels were determined using qRT-PCR. PTTG1 mRNA level was normalized to 
GAPDH and are shown relative to the negative control group. (B) ACHN ccRCC 
cells were transfected with siRNF20 and/or siSREBP1, and relative mRNA levels 
were determined using qRT-PCR. PTTG1 mRNA expression data were normalized 
to that of GAPDH, and all mRNA levels are presented relative to the negative 
control group. #P < 0.05 versus negative control; ##P < 0.01 versus negative control; 
*P < 0.05. (C) ACHN ccRCC cells were infected with SREBP1c adenovirus and 
were transfected with PTTG1 siRNA. After incubation for 48 hours, western 
blotting analyses were performed with indicated antibodies. (D) ACHN ccRCC 
cells were transfected with siControl or siRNF20. After incubation for 48 hours, 














































Figure 38. RNF20 suppresses SREBP1c-mediated PTTG1 promoter activation. 
(A) SRE motifs and E-Box sequences in PTTG promoters from several species.  
(B) HEK293 cells were co-transfected with luciferase reporter plasmids containing 
PTTG1 promoter and expression vectors for β-gal, RNF20, and/or SREBP1c. Total 
cell lysates were subjected to luciferase and β-galactosidase assays. Data are 
presented from three independent experiments performed in triplicate. RLU, 













































Figure 39. PTTG1 is upregulated in ccRCC, accompanied with poor prognosis. 
(A) qRT-PCR analysis of PTTG1 mRNA levels in patient-matched ccRCC tumors 
and normal kidney samples. PTTG1 mRNA expression was normalized to that in 
matched normal kidney samples. (B) Normalized RNA-Seq reads of PTTG1 in 
ccRCC tumors, and normal kidney samples were obtained from TCGA ccRCC 
project. (C) PTTG1 expression was analyzed in ccRCC according to tumor stages. 
RNA-Seq data were obtained from TCGA. ###P < 0.001 versus normal kidney; 
***P < 0.001. (D) Correlations between RNF20 and PTTG1 mRNA levels in 
ccRCC tumor samples were identified in data from TCGA using Pearson 
correlation tests. Numbers of cases (n), Pearson correlation coefficients (r), and the 
P values (P) are indicated. (E) Kaplan–Meier survival analyses of ccRCC patients 
were performed in low and high PTTG1 expression groups, and differences were 
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multiple oncogenic factors, including cell-cycle regulators (Chintharlapalli et al., 
2007; Li et al., 2014). Thus, I determined the effects of betulin on SREBP 
inhibition and assessed its anti-tumorigenic properties in ccRCC cells. Following 
treatment of VHL wild-type ACHN and VHL-depleted A498 ccRCC cells with 
betulin, nuclear SREBP1 protein was decreased in a dose-dependent manner, 
whereas the precursor form of SREBP1 was unaffected (Figure 40A), indicating 
that betulin represses SREBP1 processing. Simultaneously, protein levels of 
PTTG1 and cell-cycle regulators including cyclin B1 and E were decreased in 
betulin-treated ccRCC cells (Figure 40A). Moreover, betulin treatments led to 
decreased protein expression of the lipogenic enzymes FASN and SCD1    
(Figure 40A). To explore whether betulin suppresses ccRCC cell growth, I 
measured its effects on cell proliferation in ACHN and A498 cells (Figures 40B 
and 40C) and showed dose dependent anti-proliferative effects. Subsequently, to 
determine whether enhanced ccRCC cell proliferation following RNF20 
suppression might be required for activated SREBP, ccRCC cells were treated with 
betulin and RNF20 siRNA. Consistent with above data (Figure 28D), ccRCC cell 
proliferation was elevated in the presence of RNF20 siRNA, and betulin attenuated 
cell growth under these conditions (Figures 41A and 41B). Moreover, RNF20 
suppression in ccRCC cells augmented the expression of several betulin-sensitive 
genes that are involved in lipogenesis and cell cycle regulation (Figures 41C and 
41D). These data propose that the effects of RNF20 on cell growth and lipogenic 
and cell-cycle regulatory gene expression would be mediated by SREBP1c in 
ccRCC cells. These gene expression changes also corresponded with decreased 










Figure 40. The SREBP inhibitor betulin inhibits ccRCC cell proliferation.   
(A) ACHN and A498 ccRCC cells were treated with increasing concentrations of 
betulin for 12 hours, and total cell lysates were then subjected to SDS-PAGE and 
western blotting analyses with indicated antibodies. pSREBP1, precursor SREBP1; 
nSREBP1, nuclear SREBP1. (B and C) ACHN and A498 ccRCC cells were treated 
with or without betulin, and cell proliferation rates were determined using CCK-8 
assays. Data are presented as means ± SD of five individual samples. CCK-8, Cell 










































Figure 41. Betulin efficiently inhibits cell proliferation in ccRCC cells with or 
without RNF20 suppression. (A and B) ACHN and A498 ccRCC cells were 
transfected with siControl or siRNF20. Then, cell proliferation rates were 
determined using CCK-8 assays. Data are presented as means ± SD of five 
individual samples. CCK-8, Cell Counting Kit-8; *P < 0.05; ***P < 0.001; n.s., 
not significant. (C and D) ACHN and A498 ccRCC cells were transfected with 
siControl or siRNF20. After transfection for 24 hours, cells were treated with 
betulin (10 μM) for 24 hours, and relative mRNA levels were determined using 
qRT-PCR. Subsequently, mRNA expression was normalized to that of the GAPDH 
gene. Data are presented as means ± SD of three individual samples. #P < 0.05 
versus negative control; ##P < 0.01 versus negative control; ###P < 0.001 versus 




































In accordance with the reduced expression of cell-cycle regulatory genes, including 
PTTG1 and certain cyclins (Figure 40A), betulin slightly but substantially 
increased numbers of ccRCC cells in the G1 phase (Figure 42B). These data 
suggest that betulin would repress ccRCC cell proliferation by regulating SREBP1-
dependent lipogenesis and cell cycle progression. 
 
SREBP1c controls ccRCC cell growth through dual mode actions that affect 
cell cycle and lipid metabolism. 
The present data suggest a relationship between PTTG1 and lipid 
metabolism during SREBP1c-dependent ccRCC cell proliferation. Thus, I 
investigated the effects of PTTG1 on lipid metabolism and/or cell proliferation in 
SREBP1c-overexpresing ccRCC cells (Figure 43A). PTTG1 suppression did not 
alter mRNA expression of SREBP1c or FASN (Figure 43B), whereas ectopic 
SREBP1c expression promoted mRNA expression of PTTG1 and cell-cycle 
regulators including PCNA, cyclin A, D1, and E in ccRCC cells (Figures 43B and 
43C). In contrast, suppression of PTTG1 expression in ccRCC cells downregulated 
these cell-cycle proteins (Figure 43C). In addition, PTTG1 suppression inhibited 
cell proliferation in both control and SREBP1c-overexpressing ACHN cells  
(Figure 43D). Next, I determined PTTG1 expression and cell proliferation in the 
presence or absence of the ACC inhibitor TOFA or the FASN inhibitor C75 (Figure 
43A). As shown in Figure 44A, TOFA and C75 treatments reduced intracellular 
triglyceride accumulation in ACHN cells. However, reductions in lipogenic activity 
by TOFA or C75 did not greatly effect mRNA expression of PTTG1 or cell-cycle 










Figure 42. The SREBP inhibitor betulin represses lipogenesis and cell cycle 
progression in ccRCC cells. (A) ACHN ccRCC cells were treated with betulin  
(10 μM). After incubation for 24 hours, cells were fixed and stained with BODIPY 
(green) and DAPI (blue). Images were acquired using a confocal microscope. 
DAPI, 4‟,6-diamidino-2-phenylindole; Scale bar, 10 μm. (B) ACHN ccRCC cells 
were treated with betulin (10 μM) for 24 hours, were fixed and stained with 
propidium iodine, and DNA contents were analyzed using flow cytometry. 










































Figure 43. SREBP1c controls ccRCC cell growth through coordinated 
regulation of cell cycle and fatty acid metabolism. (A) Experimental scheme to 
test the effects of siRNA-mediated suppression of PTTG1 or FASN, and 
pharmacological inhibition of lipogenic genes including FASN and ACC.       
(B and C) Lentivirus-mediated Mock (as a negative control) or SREBP1c 
overexpressing ACHN cells were transfected with PTTG1 siRNA for 48 hours. 
Relative mRNA levels were then determined using qRT-PCR and were normalized 
to that of GAPDH. Expression data are presented relative to the negative control as 
means ± SD of three individual samples. #P < 0.05 versus negative control;     
##P < 0.01 versus negative control. (D) Relative growth rates of cells described in 
Figures 43B and 43C were measured using CCK-8 assays. CCK-8, Cell Counting 









































Figure 44. Suppression of lipogenic activity does not change expression of 
PTTG1 and cell cycle genes. (A) ACHN ccRCC cells were treated with TOFA  
(10 μg/ml) or C75 (10 μg/ml) for 24 hours, and intracellular triglyceride contents 
were measured. (B) ACHN ccRCC cells were treated with TOFA (10 μg/ml) or 
C75 (10 μg/ml) for 24 hours, and relative mRNA expression levels were 
determined using qRT-PCR. PTTG1 mRNA levels are presented relative to those in 
the vehicle control group. n.s., not significant. (C) Relative growth rates of cells 
described in Figures 44A and 44B were measured using CCK-8 assays. CCK-8, 
Cell Counting Kit-8; **P < 0.01; n.s., not significant. (D and E) ACHN ccRCC 
cells were treated with TOFA (10 μg/mL) or C75 (10 μg/mL) for 24 hours. Relative 
mRNA levels were normalized to that of the GAPDH gene, and are presented 
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siRNA-mediated suppression of FASN did not greatly alter mRNA levels of 
PTTG1 and cell-cycle regulatory genes (Figures 45A and 45B). However, both 
C75-mediated pharmacological inhibition of FASN and siRNA-driven FASN 
knockdown led to significant decreases in ccRCC cell proliferation (Figures 44C 
and 45C). Furthermore, pharmacologic and genetic inhibition of FASN reduced the 
effects of SREBP1c overexpression on cell growth in ACHN cells, implying that 
inhibition of lipogenesis might attenuate ccRCC cell proliferation via SREBP1c-
dependent pathways (Figures 45C and 45D). Taken together, these data show that 
PTTG1 and de novo lipogenic pathways in ccRCC cells are independently 
regulated by SREBP1c, which would influence cell proliferation via lipid 
metabolism and cell cycle regulation. 
 
RNF20 overexpression attenuates tumor growth in ccRCC xenografts. 
To validate the present roles of RNF20 in ccRCC tumor growth in vivo, I 
performed xenograft experiments in nude mice. In ACHN xenograft tumors, 
ectopic RNF20 expression significantly inhibited tumor growth rates (Figures 46A 
and 46B) and led to decreased tumor masses (Figure 46C), indicating that RNF20 
could suppress ccRCC tumor growth. In addition, subsequent western blot analyses 
showed that ectopic expression of RNF20 inhibited protein expression of SREBP1, 
PTTG1, and FASN in xenograft tumors (Figure 46D). Moreover, RNF20 
significantly attenuated mRNA expression of SREBP1c, cell-cycle regulators, and 
lipogenic genes in xenograft tumors (Figure 46E). In H&E staining experiments, 
ACHN tumors with elevated RNF20 expression exhibited reduced numbers of cells 








Figure 45. SREBP1c controls ccRCC cell growth through dual modes of action 
that affect cell cycle and lipid metabolism. (A and B) Lentivirus-mediated Mock 
(negative control) or SREBP1c overexpressing ACHN cells were transfected with 
FASN siRNA for 48 hours, and mRNA levels were determined using qRT-PCR. 
Relative mRNA expression was normalized to that of the GAPDH gene, and is 
shown relative to those in the negative control group. #P < 0.05 versus negative 
control; ##P < 0.01 versus negative control; n.s., not significant. (C) Relative 
proliferation rates of cells described in Figures 45A and 45B were monitored using 
CCK-8 assays. CCK-8, Cell Counting Kit-8; *P < 0.05; **P < 0.01. (D) ACHN 
ccRCC cells stably overexpressing Mock or SREBP1c following lentiviral 
transduction. After treatment with C75, cell proliferation rates were monitored 








































Figure 46. RNF20 overexpression attenuates tumor growth in xenograft mice. 
(A) Subcutaneous tumors of ACHN cells expressing either Mock or ectopic RNF20 
were generated in female BALB/c nude mice (each group includes ten tumors from 
five mice). Representative images of tumors dissected at the end of the study 
showing the effect of RNF20 overexpression on the growth of in vivo xenograft 
tumors. Scale bar, 10 mm. (B) Xenograft tumor volumes (mm3) of ACHN cells 
with or without ectopic RNF20 expression were determined over 35 days. The 
graph shows tumor volumes as mean ± SEM. (C) End-point xenograft tumor 
weights (mg) were measured and plotted. (D) Expression levels of RNF20, 
nSREBP1, PTTG1, and FASN protein in ACHN xenograft tumors were monitored 
using western blotting analyses. nSREBP1, nuclear SREBP1. (E) The effects of 
ectopic RNF20 expression on cell cycle, and lipogenic gene expression were 
determined using qRT-PCR analyses in ACHN xenograft tumors. Relative mRNA 
levels were normalized to GAPDH mRNA level and are shown relative to the 

































that ectopic RNF20 expression reduced lipid accumulation (Figure 47). 
Furthermore, Ki67 staining analyses revealed that exogenous RNF20 reconstitution 
decreased cell proliferative properties in xenograft tumors (Figure 47). Moreover, 
terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) analyses 
showed that RNF20 overexpression induced apoptosis in xenograft tumors  
(Figure 47). I also observed increased mRNA expression of the pro-apoptotic genes 
including Bax, Bid, and Caspase-3 following ectopic expression of RNF20, 
whereas mRNA expression of the anti-apoptotic genes Bcl-2, cIAP-2, and XIAP 
were reduced (Figure 48). These in vivo data suggest that RNF20 would act as a 
tumor suppressor by inhibiting SREBP1c-mediated lipogenesis and cell cycle 
regulation in ccRCC. In summary, the present data suggest that RNF20 
downregulation in ccRCC allows for SREBP1c induction, which enhances the 













Figure 47. RNF20 overexpression reduces lipid storage and cell viability in 
ccRCC xenografts. Histologic analyses of xenograft tumors. Representative 
hematoxylin and eosin (H&E) and Oil Red O staining of Mock or RNF20-
transduced ACHN xenograft tumors. IHC of xenograft tumors stained with Ki67 
and TUNEL. TUNEL, terminal deoxynucleotidyl transferase dUTP nick end 













































Figure 48. RNF20 regulates the expression of pro-apoptotic and anti-apoptotic 
genes in xenograft tumors. The effects of ectopic RNF20 expression on apoptotic 
gene expression in ACHN xenograft tumors were determined using qRT-PCR 
analyses. Relative mRNA expression was normalized to that of the GAPDH gene, 
and is presented relative to those in the Mock control group. **P < 0.01;     





































It is well established that constitutive activation of HIF due to the loss of 
VHL in ccRCC causes pathogenic metabolic alterations (Kaelin, 2008; Shen and 
Kaelin, 2013). However, kidney-specific VHL deficient mice did not exhibit 
ccRCC-like metabolic phenotypes (Rankin et al., 2006), suggesting additional 
mechanisms of ccRCC tumor formation. The present data demonstrate that RNF20 
downregulation promotes ccRCC tumorigenesis by activating SREBP1c. In 
agreement, several lines of evidence support the idea that RNF20 would suppress 
ccRCC tumor growth. Among these, RNF20 expression was decreased in ccRCC 
tumors compared with normal kidney tissues (Figure 25, A-E) and was inversely 
correlated with SREBP1 and lipogenic gene expression (Figure 30, A-I; Figure 31, 
A-E). Accordingly, low RNF20 expression was strongly associated with poor 
survival in ccRCC patients regardless of VHL mutation status (Figure 27, A-C), 
indicating that RNF20 expression is inversely correlated with ccRCC progression. 
In agreement, ectopic expression of RNF20 repressed SREBP1c and cell 
proliferation in both VHL wild-type and depleted ccRCC cell lines (Figures 28B, 
33A, and 35B), but did not affect proliferation of in HRCE and HEK293 normal 
kidney cells with high basal RNF20 expression (Figures 25F and 29B). Finally, 
RNF20 overexpression decreased tumor growth in ccRCC xenografts and was 
accompanied by reduced expression of SREBP1c and its target genes (Figure 46). 
Previous epigenetic studies have shown that several tumor suppressor genes play 
roles in ccRCC (Arai et al., 2009; Ricketts et al., 2012). For example, it has been 
reported that the RNF20 promoter contains prominent CpG islands and is 
hypermethylated in breast cancer tumors (Shema et al., 2008). Correspondingly, 
170 
treatment of ACHN ccRCC cells with the DNA methyltransferase inhibitor RG108 
led to a substantial increase in RNF20 mRNA expression, but this was not observed 
in HEK293 cells (Figure 26B), implying that RNF20 promoter hypermethylation, 
at least partly, may serve to dampen RNF20 expression in ccRCC. 
In agreement with previous observations of abundant lipid storage and 
increased lipogenesis in ccRCC (Drabkin and Gemmill, 2010; Li and Kaelin, 2011), 
the present data show upregulated SREBP1 and lipogenic activities (Figure 30, A-I; 
Figures 31A and 31B). However, mRNA levels of SREBP2 and its target gene, 
such as HMGCR, were decreased in ccRCC tumors (Figure 32, A-D), indicating 
that SREBP1 and de novo lipogenesis might play primary oncogenic roles. These 
observations warrant consideration of pharmacological inhibitors of lipogenesis as 
anti-cancer drugs for ccRCC. In accordance, the FASN inhibitor C75 and the SCD1 
inhibitor A939572 potently inhibited tumor growth and invasiveness of ccRCC 
(Horiguchi et al., 2008; von Roemeling et al., 2013), and the SREBP inhibitor 
betulin repressed ccRCC cell proliferation by inhibiting SREBP1 and lipogenesis 
regardless of VHL gene mutations (Figure 40). In addition, betulin potently 
abolished the increases cell proliferation and lipogenic activity that followed 
suppression of RNF20 (Figure 41). Given the hyperactivation of SREBP1 and 
lipogenesis along with RNF20 downregulation in ccRCC (Figures 25, 30, and 31), 
unfettered SREBP1 may promote ccRCC tumor development via lipogenic 
activation. Therefore, it is plausible that SREBP1 and lipogenic pathways are 
exploitable therapeutic targets against ccRCC. 
SREBP1c has been associated with de novo lipogenesis and cell cycle 
progression (Bengoechea-Alonso and Ericsson, 2006; Jeon et al., 2013; Williams et 
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al., 2013). Moreover, cyclin-dependent kinase 1 (CDK1)/cyclin B phosphorylates 
and activates SREBP1c during mitosis (Bengoechea-Alonso and Ericsson, 2006). 
Similarly, the SREBP-responsive miRNA miR-33 reportedly inhibited CDK6 and 
cyclin D1 expression, thereby reducing cell proliferation and cell cycle progression 
in certain cancer cells (Cirera-Salinas et al., 2012). In glioma and cervical cancers, 
suppression of SREBP1 represses tumor growth by inducing G1 cell cycle arrest 
and apoptosis (Bengoechea-Alonso and Ericsson, 2006; Williams et al., 2013). In 
addition, it has been shown that betulin inhibits lung cancer cell proliferation by 
downregulating cell-cycle regulators such as cyclin B1, D, and E (Li et al., 2014). 
In this study, I showed that PTTG1 is also involved in cell cycle progression and 
tumorigenesis in ccRCC and acts as a novel target gene of SREBP1c. PTTG1 (also 
known as securin, EAP1, and TUTR1) is an anaphase inhibitor that prevents 
premature chromosome separation by inhibiting separase activity (Draviam et al., 
2004; Jallepalli and Lengauer, 2001). Previous studies have suggested that PTTG1 
participates in various pathways that modulate the cell cycle, proliferation, and 
survival. For example, PTTG1 has been shown to interact with p53 and prevent 
p53-dependent transcription and apoptosis (Bernal et al., 2002; Yu et al., 2000). 
Further, PTTG1 promotes the expression of several genes including c-Myc, cyclin 
D3, FGF2, and MMP2, potentially acting as a transcription factor (Dominguez et 
al., 1998; Tong and Eigler, 2009; Tong et al., 2007). In addition, it has been showed 
that PTTG1 is overexpressed in certain tumors including pituitary, thyroid, glioma, 
hepatic, colorectal, and renal cancers, and may drive tumorigenesis (Vlotides et al., 
2007; Wondergem et al., 2012). In the present study, I found that high expression of 
PTTG1 was closely associated with advanced tumor stages and poor survival in 
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ccRCC patients (Figures 39D and 39E). Moreover, SREBP1c potently stimulated 
mRNA and protein expression of PTTG1 and several cell-cycle regulators, leading 
to cancer cell proliferation in ccRCC (Figures 35 and 37). In contrast, RNF20 
overexpression repressed PTTG1 in both ccRCC cells and xenograft tumors 
(Figures 37A, 46D, and 46E), and RNF20 suppression led to increased mRNA and 
protein levels of PTTG1 (Figures 37B and 37D). Accordingly, PTTG1 expression 
was negatively associated with RNF20 expression, reflecting modulation of 
SREBP1c in ccRCC tumor tissues (Figure 39D) and suggesting that RNF20 
downregulation would promote ccRCC development and progression, in part by 
upregulating PTTG1. In agreement, siRNA knockdown of PTTG1 led to decreased 
mRNA expression of cell-cycle regulatory genes without changing lipogenic 
activity (Figures 43B and 43C). Furthermore, PTTG1 suppression attenuated the 
effects of activated SREBP1c on ccRCC cell proliferation (Figure 43D). Therefore, 
it is likely that RNF20-SREBP1c-PTTG1 axis is central to ccRCC cell proliferation 
and tumorigenesis. 
It is well established that SREBP1 regulates lipid metabolism, 
predominantly by increasing de novo lipogenesis. Thus, I tested whether 
lipogenesis is associated with PTTG1 expression in the presence of genetic and 
pharmacological inhibitors of de novo lipogenesis. In these experiments, mRNA 
expression of PTTG1 in ACHN ccRCC cells was not affected by pharmacological 
inhibition of lipogenesis using TOFA or C75 (Figure 44B) or by siRNA-mediated 
knockdown of FASN (Figure 45A), suggesting that SREBP1c would stimulate 
PTTG1 in a lipogenesis-independent manner. Thus, SREBP1c may affect lipid 
metabolism and cell cycle progression by regulating different set of genes, which 
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eventually coalesce to drive tumor development in ccRCC. Many studies have 
demonstrated that lipogenic inactivation by TOFA or C75 induces cell cycle arrest 
and apoptosis in several cancers, including lung, colorectal, and renal cancers 
(Horiguchi et al., 2008; Wang et al., 2009). Hence, future studies are required to 
clarify whether lipogenic pathways might affect PTTG1 and cell cycle progression 
in other tissues and/or cancers. 
According to the present data, I propose a model in which RNF20 acts as a 
tumor suppressor by inhibiting SREBP1c-mediated lipogenesis and cell cycle 
regulation (Figure 49). Conversely, these data indicate that RNF20 downregulation 
promotes tumorigenesis by activating SREBP1c in ccRCC tumors. In addition, I 
identified a novel mechanism by which SREBP1c stimulates cell cycle progression 
by inducing PTTG1 in ccRCC, and I suggest that RNF20 could modulate the 
SREBP1c-lipogenesis axis and the SREBP1c-PTTG1 axis. Taken together, these 
findings implicate RNF20 as a novel tumor suppressor in ccRCC and suggest 
clinical benefits of therapeutic approaches that target components of the RNF20-










Figure 49. Proposed model illustrating tumor-suppressive functions of RNF20 
against SREBP1-mediated lipogenesis and cell cycle progression in ccRCC. 
RNF20 downregulation and SREBP1 upregulation are associated with poor 
prognosis in ccRCC patients. Downregulation of RNF20 induces SREBP1 
hyperactivation, leading to ccRCC tumorigenesis. SREBP1 controls cell cycle 
regulation by PTTG1 as a novel SREBP1c target gene. In addition, the small-
molecule SREBP inhibitor betulin blocks cell proliferation by inhibiting 
lipogenesis and inducing G1 cell cycle arrest. Taken together, RNF20 
downregulation promotes tumorigenesis via SREBP1-mediated lipogenesis and 

























CONCLUSION & PERSPECTIVES 
 
Lipid metabolism is essential for cell growth and survival. Thus, 
dysregulation of lipid metabolism is closely associated with metabolic disorders 
and tumorigenesis. SREBP1c is a key transcription factor for lipid metabolism. In 
last decades, enormous efforts have been made to elucidate the regulatory 
mechanisms and functions of SREBP1c in physiological and pathophysiological 
conditions. Nonetheless, the regulatory mechanisms that control SREBP1c 
turnover in response to fasting status are not thoroughly elucidated. To investigate 
which factors are involved in stability and activity of SREBP1c, I have tried to 
identify SREBP1c-interacting proteins. Through affinity purification and mass 
spectrometry analyses, RNF20 has been identified as an E3 ubiquitin ligase for 
SREBP1c. Furthermore, to investigate the pathophysiological roles of RNF20-
SREBP1c axis on cell proliferation in cancers, I have attempted to identify 
SREBP1c target genes that might be involved in cell cycle regulation using RNA-
Seq analyses with wild-type and SREBP1c deficient mice. As a novel target gene of 
SREBP1c, PTTG1 regulate cell cycle genes and cell proliferation in ccRCC cells. 
Collectively, these data provide new insights to understand novel mechanism 
between lipid metabolism and cell cycle progression. 
 
1. RNF20 is an E3 ubiquitin ligase for SREBP1c 
SREBP1c governs de novo lipogenesis by stimulating its target genes, 
including FASN, ACC, SCD1, and ELOVL6 (Eberle et al., 2004b; Kim and 
Spiegelman, 1996; Kumadaki et al., 2008). SREBP1c is sensitively regulated by 
177 
nutritional and hormonal changes to maintain energy homeostasis. SREBP1c is 
activated by insulin, whereas SREBP1c is suppressed by glucagon (Horton et al., 
1998a; Kim et al., 1998). Although SREBP1c-mediated lipogenic program is 
rapidly repressed by nutritional deprivations, the factors that are involved in the 
suppression of SREBP1c activity during fasting have not been clearly identified. In 
the chapter one, I demonstrated that RNF20 is an E3 ubiquitin ligase for SREBP1c 
and acts as a negative regulator of hepatic lipid metabolism through PKA-
dependent SREBP1c degradation. 
RNF20 has been firstly identified as yeast Bre1 and possesses a RING 
finger domain that primarily functions as an E3 ligase for histone H2B 
monoubiquitination, which regulates expression of certain genes (Hwang et al., 
2003; Kim et al., 2005; Wood et al., 2003). Also, RNF20 plays various roles in 
transcription, DNA damage responses, and stem cell differentiation (Cole et al., 
2015; Shema et al., 2008). Moreover, it has been suggested that RNF20 acts as a 
tumor suppressor in breast and colorectal cancers (Shema et al., 2008; Tarcic et al., 
2016). Nevertheless, it has not been thoroughly investigate whether RNF20 might 
be involved in lipid metabolism. 
SREBP1c is very unstable and rapidly degraded by the proteasome 
(Hirano et al., 2003; Hirano et al., 2001). It has been reported that SREBP1c is 
phosphorylated by GSK-3β, which leads to F-box and WD repeat domain-
containing 7 (FBXW7)-dependent ubiquitination of SREBP1c (Punga et al., 2006; 
Sundqvist et al., 2005). However, a recent in vivo study has been reported that 
inhibition FBXW7 does not alter the expression of SREBP1c or lipogenic genes in 
the liver (Kumadaki et al., 2011). It is of interest to note that RNF20 would induce 
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polyubiquitination and degradation of SREBP1c upon PKA activation, whereas 
PKA activation did not change the level of FBXW7. Given that PKA plays a 
crucial role in catabolic responses, PKA activation with forskolin decreased 
lipogenic gene expression with an increase in RNF20, whereas suppression of 
RNF20 reversed the effect of forskolin on lipogenic gene expression, implying that 
RNF20 might mediate PKA signaling cascade to downregulate hepatic lipid 
metabolism via SREBP1c degradation. Here, I found out a novel mechanism of 
SREBP1c regulation by RNF20 during nutritional deprivation. Knowledge 
regarding this process enhances the molecular mechanisms of how SREBP1c is 
able to turn off hepatic lipid metabolism during nutritional deprivation. 
 
2. RNF20 is downregulated in ccRCC 
In cancer cells, elevated lipid metabolism plays an important role by 
providing building blocks for tumor growth (DeBerardinis et al., 2008; Schulze and 
Harris, 2012). Particularly, ccRCC, the most common subtype of kidney cancers, is 
characterized by ectopic intracellular lipid accumulation (Rezende et al., 1999; 
Valera and Merino, 2011). Metabolic alteration and pathogenesis are characterized 
by constitutive activation of HIF due to loss of the VHL in 90% of ccRCC tumors 
(Kaelin, 2008; Shen and Kaelin, 2013). Nonetheless, kidney-specific VHL deficient 
mice fail to exhibit ccRCC-like metabolic phenotypes and tumor formation, 
implying that additional mechanisms might be present in ccRCC (Rankin et al., 
2006). The finding that RNF20 acts as a negative regulator of de novo lipogenesis 
by inhibition of SREBP1c prompted me to test whether RNF20 might be 
dysregulated in ccRCC tumors. 
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In the chapter two, I have shown that RNF20 is downregulated and 
exhibits tumor-suppressive functions in ccRCC. Several lines of evidence from in 
vivo and in vitro data support the above idea. First, RNF20 expression was 
decreased in ccRCC tumors compared with normal kidney tissues. Furthermore, 
low RNF20 expression was associated with poor survival regardless of VHL 
mutation status in ccRCC patients, implying that RNF20 might oppose ccRCC 
progression in a VHL-independent manner. Second, ectopic expression of RNF20 
repressed SREBP1c and cell proliferation in both VHL wild-type ACHN and VHL 
depleted A498 ccRCC cell lines. Third, the levels of SREBP1c and tumor growth 
were reduced by RNF20 overexpression in vivo ccRCC xenograft tumors. 
RNF20 has been reported as a putative tumor suppressor (Shema et al., 
2008), possibly functioning through interaction with p53 and its presence at the 
promoter of p53 target genes (Kim et al., 2005). RNF20-promoted histone H2B 
monoubiquitination is elevated at the coding regions of p53 target genes upon their 
activation (Minsky et al., 2008). Suppression of RNF20 results in a decrease in p53 
expression, which leads to increase in cell migration and tumorigenesis. Also, 
downregulation of RNF20 increases tumor growth (Shema et al., 2008). 
RNF20 promoter contains prominent CpG islands and is hypermethylated 
in breast cancer tumors (Shema et al., 2008). Consistent with these reports, I 
observed that DNA methyltransferase inhibitor RG108 treatment to ACHN ccRCC 
cell lines substantially increased the level of RNF20 mRNA, but not in HRCE and 
HEK293 normal kidney cell lines, implying that RNF20 promoter 
hypermethylation, at least partly, may serve to dampen RNF20 expression in 
ccRCC. Together, I suggest that RNF20 would act as a potential tumor suppressor 
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and is downregulated in ccRCC. 
 
3. SREBP1c promotes lipogenesis and cell proliferation in ccRCC 
Accumulating evidences have demonstrated that activated SREBP1c 
enhances lipogenesis in certain cancers (Griffiths et al., 2013; Guo et al., 2014). In 
addition, SREBP1c promotes lipid metabolism and tumor development, 
potentiating progression and migration, leading to poor prognosis in certain cancers 
(Guo et al., 2009; Huang et al., 2012). Previous studies have shown that lipogenic 
enzymes such as FASN and SCD1 are increased in various cancers (Igal, 2010; 
Menendez and Lupu, 2007). Moreover, drugs targeting against SREBP1c-driven 
lipogenesis have been shown as anti-cancer effects in glioblastoma therapy (Guo et 
al., 2009). However, it remains unclear whether SREBP1 and lipogenic genes 
might be associated with ectopic lipid storage and cell proliferation in ccRCC. 
In this study, I demonstrated that SREBP1c and lipogenic activities are 
upregulated in ccRCC tumors and promote ccRCC cell proliferation. In TCGA 
analyses, the mRNA levels of SREBP1 and lipogenic genes were elevated in 
ccRCC tumors compared with normal kidney tissues, which were correlated with 
poor prognosis in ccRCC patients. In addition, I verified that ectopic SREBP1c 
overexpression stimulated ccRCC cell proliferation. These observations warrant a 
potential consideration of pharmacological inhibitors for lipogenesis as anti-cancer 
drugs against ccRCC. Accordingly, the SREBP inhibitor betulin repressed ccRCC 
cell proliferation by inhibiting SREBP1 and lipogenesis. Given the hyperactivation 
of SREBP1 and lipogenesis along with RNF20 downregulation in ccRCC, 
unfettered SREBP1 may promote ccRCC tumor development via lipogenic 
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activation. Therefore, it is plausible that SREBP1 and lipogenic pathways might be 
potential therapeutic targets against ccRCC. 
 
4. SREBP1c-PTTG1 axis potentiates cell cycle progression and 
tumorigenesis 
Recently, it has been reported that SREBP1c is involved in not only fatty 
acid synthesis but also cell cycle progression (Bengoechea-Alonso and Ericsson, 
2006; Jeon et al., 2013; Williams et al., 2013). For example, CDK1/cyclin B-
mediated phosphorylation stabilizes and activates SREBP1c during mitosis 
(Bengoechea-Alonso and Ericsson, 2006). In addition, miR-33, which is one of the 
SREBP-responsive miRNAs, inhibits the expression of the CDK6 and cyclin D1, 
thereby reducing cell proliferation and cell cycle progression in Huh7 and A549 
cells (Cirera-Salinas et al., 2012). In glioma and cervical cancers, suppression of 
SREBP1 represses tumor growth via inducing G1 cell cycle arrest and apoptosis 
(Bengoechea-Alonso and Ericsson, 2006; Williams et al., 2013). Furthermore, it 
has been shown that betulin inhibits lung cancer cell proliferation by 
downregulating cell-cycle regulators such as cyclin B1, D, and E (Li et al., 2014). 
Here, I have identified that PTTG1 is a novel target gene of SREBP1c and 
involved in cell cycle progression and tumorigenesis in ccRCC. PTTG1 (also 
known as securin, EAP1, and TUTR1) is an anaphase inhibitor that prevents 
premature chromosome separation through inhibition of separase activity and also 
interacts with p53, which leads to inhibit p53-dependent transcription and 
apoptosis (Draviam et al., 2004; Jallepalli and Lengauer, 2001). Besides, PTTG1 
appears to function as a transcription factor, which promotes the transcription of 
182 
several genes, such as c-Myc, cyclin D3, FGF2, and MMP2 (Dominguez et al., 
1998; Tong and Eigler, 2009). Thus, it seems that PTTG1 participates in several 
key cellular events such as gene transcription, cell transformation, angiogenesis, 
metabolism, apoptosis, DNA repair, genetic instability, and mitotic control 
(Bradshaw and Kakar, 2007; Vlotides et al., 2007). Recently, PTTG1 has been 
categorized as an oncogene because PTTG1 is overexpressed in numerous tumors 
including pituitary, thyroid, glioma, hepatic, colorectal, and renal cancers 
(Bradshaw and Kakar, 2007; Vlotides et al., 2007). In accordance with the previous 
reports (Wondergem et al., 2012), high PTTG1 expression was associated with 
advanced tumor stage and poor survival in ccRCC, whereas PTTG1 expression was 
negatively correlated with RNF20 expression. Notably, SREBP1c potently 
stimulated the levels of PTTG1 mRNA, protein, and several cell-cycle regulators, 
leading to cancer cell proliferation in ccRCC. In contrast, PTTG1 knockdown via 
siRNA decreased the mRNA levels of cell-cycle regulatory genes without change 
of lipogenic activity. In addition, pharmacological inhibition of lipogenesis with 
TOFA or C75 did not change the mRNA level of PTTG1 in ccRCC cell lines. 
These data indicate that SREBP1c could stimulate PTTG1 level, probably, in a 
lipogenesis-independent manner. Together, these data suggest that SREBP1c could 
regulate not only lipid metabolism but also cell cycle progression by regulating 
different set of genes, which would eventually coalesce to drive tumor 
development in ccRCC. Nevertheless, further studies are required to clarify 
whether lipogenic pathway might affect PTTG1 and cell cycle progression in other 
tissues and/or different types of cancers. 
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In conclusion, I have elucidated a novel mechanism of lipid metabolism 
which RNF20 downregulates SREBP1c upon fasting. Furthermore, this work 
provides a clue to understand how SREBP1c is rapidly regulated by fasting signals 
to prevent futile lipogenic activation. Because there is a positive correlation 
between lipogenic activity and metabolic complications such as obesity, NAFLD, 
and certain cancers, it is likely that RNF20 might be a metabolic tumor suppressor 
in certain cancers associated with increased lipid metabolism. In addition, I have 
investigated whether RNF20 might be involved in tumorigenesis in ccRCC, which 
is characterized by ectopic intracellular lipid storage. This study indicates that 
downregulation of RNF20 stimulates tumorigenesis following SREBP1c activation 
in ccRCC, accompanied with poor prognosis. Conversely, RNF20 overexpression 
repressed lipogenesis and cell proliferation by inhibiting SREBP1c in cultured 
ccRCC cells and xenograft studies. Notably, PTTG1 was identified as a novel 
SREBP1c target gene that plays a crucial role in cell cycle control in ccRCC. Taken 
together, RNF20 suppresses tumorigenesis by inhibiting SREBP1c-mediated 
lipogenesis and cell cycle regulation in ccRCC. I believe that this work establishes 
the key role of RNF20-SREBP1c axis for the control of lipogenesis and cell cycle 
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지방대사는 에너지 항상성, 싞호젂달 경로, 세포막 구조를 
조젃함으로써 세포의 성장과 생졲에 중요핚 역핛을 수행핚다. 그러므로 
지방대사의 이상 조젃은 대사성 질환 및 종양 형성과 밀접하게 연관되어 
있다. 간에서 다량으로 발현하는 젂사인자인 sterol regulatory element-
binding protein 1c (SREPB1c)는 인슐린에 의해 활성화되어 지방대사물 
생합성을 촉짂하는 역핛을 관장핚다. 반면 공복시 SREBP1c는 
억제됨으로써 불필요핚 지방대사물의 생합성을 제어하는데 그에 대핚 
기젂 연구가 불분명핚 상황이다. 이와 함께 암세포에서 SREBP1c의 
활성화는 종양의 발생, 짂행 및 젂이를 촉짂함으로써 궁극적으로 환자의 
낮은 생졲 예후와 연관되어 있다. 그러나 암세포에서 SREBP1c가 어떻게 
지방대사물의 축적과 종양 발생을 촉짂하는지에 대해서는 분자수준의 
연구가 부족핚 상황이다. 
본 연구를 통해 SREBP1c 젂사인자의 유비퀴틴화를 통핚 분해를 
매개하는 E3 ubiquitin ligase로 ring finger protein 20 (RNF20)을 동정하였다. 
간세포에서 RNF20는 단식 조건에서 활성화되는 protein kinase A (PKA) 
싞호젂달을 거쳐 그 발현이 증가하며, 이로 인해 SREBP1c 활성 및 
지방대사물 생합성 프로그램이 통제되는 새로운 기젂을 규명하였다. 
나아가 SREBP1c와 지방대사물 생합성이 증가되어 있는 db/db 생쥐 
모델의 간 조직 특이적 RNF20 과발현은 SREBP1c와 지방대사물 생합성 
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관련인자들의 발현 감소를 통하여 궁극적으로 지방간을 개선시켰다. 
이상의 결과들을 통하여 공복 시 RNF20가 SREBP1c를 제거함으로써 
불필요핚 지방대사물 생합성이 억제되는 지방대사 항상성 조젃 기젂을 
새롭게 제시하였다. 
과도핚 지방대사물 축적이 동반되는 싞장암에서 RNF20는 
억제되며 동시에 SREBP1c는 활성화됨을 관찰하였다. 싞장암 종양 
조직에서 RNF20 발현이 감소되어 있지만 지방대사물 생합성 관련 
유젂자의 발현은 증가되어 있으며, RNF20 발현이 낮게 관찰되는 싞장암 
환자의 낮은 생졲 예후를 발견하였다. 싞장암 세포주와 이종 이식 실험 
결과, RNF20 과발현에 의해 SREBP1c가 억제됨으로써 지방대사물 
생합성과 세포증식이 감소함을 관찰하였다. 본 연구를 통해 pituitary 
tumor-transforming gene 1 (PTTG1)을 SREBP1c의 새로운 표적 유젂자로 
동정하였으며, 싞장암 세포에서 SREBP1c에 의핚 PTTG1 유도가 
세포주기 조젃에 있어 중요핚 역핛을 수행함을 밝혔다. 또핚, 싞장암 
세포에서 유젂자 넉다운과 SREBP1c 억제 약물인 베툴린은 SREBP1c의 
저해뿐 아니라 PTTG1과 세포주기 조젃 유젂자들의 발현을 
감소시킴으로써 세포증식을 억제함을 관찰하였다. 
본 연구를 통하여 RNF20-SREBP1c 싞호젂달 경로는 지방대사물 
생합성 및 세포주기를 조젃함으로써 지방대사 항상성 유지와 싞장암 
종양 형성 과정에도 깊이 연관되어 있음을 규명하였다. 그러므로 
RNF20는 SREBP1c 제어를 통하여 지방대사 및 세포주기 조젃에 중요핚 
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기능을 담당함으로써 대사성 질환 및 특정 종양 치료제 발굴을 위핚 
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